{"gene":"CCR8","run_date":"2026-06-09T22:57:17","timeline":{"discoveries":[{"year":1997,"finding":"CCR8 (then named CY6/TER1/CKR-L1) was identified as the specific receptor for the human CC chemokine I-309 (CCL1). Transfection of the CY6 open reading frame into mouse pre-B cells conferred calcium flux and chemotaxis in response to I-309 (EC50 = 2 nM), while 20 other chemokines were inactive. Signaling was sensitive to pertussis toxin, indicating coupling to a Gi-type G protein. CCR8 is constitutively expressed in monocytes and thymus.","method":"Transfection of pre-B cell line, calcium flux assay, chemotaxis assay, pertussis toxin inhibition","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstituted receptor function in heterologous cells, confirmed by two independent labs (PMID:9207005 and PMID:9211859) with in vitro assays and mutagenesis-equivalent controls","pmids":["9207005"],"is_preprint":false},{"year":1997,"finding":"CCR8 (TER1/ChemR1/CKR-L1) stably expressed in murine pre-B 300-19 cells responds selectively to I-309 with intracellular Ca2+ mobilization and chemotaxis (Kd ~1.2 nM for 125I-I-309 binding), with no response to 20 other human chemokines tested.","method":"Stable transfection in 300-19 pre-B cells, 125I-I-309 radioligand binding, calcium mobilization, chemotaxis assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — independent replication of receptor identification with radiolabeled ligand binding affinity measurement and functional assays","pmids":["9211859"],"is_preprint":false},{"year":1998,"finding":"TARC (CCL17) and MIP-1β (CCL4) were identified as additional functional CCR8 ligands, inducing chemotaxis in CCR8-transfected Jurkat cells.","method":"Stable transfection of Jurkat cells, chemotaxis assay","journal":"European journal of immunology","confidence":"Medium","confidence_rationale":"Tier 3 / Weak — single lab, single transfection-based chemotaxis assay; later partially superseded by more selective ligand studies","pmids":["9521068"],"is_preprint":false},{"year":1998,"finding":"CCR8 is preferentially expressed in Th2-polarized T cells (human and mouse) but not Th1 cells. Mouse CCR8 is also expressed in thymus and NK1.1+CD4+ T cells. I-309 and its mouse homologue TCA-3 are potent chemoattractants for Th2-polarized cells acting through CCR8.","method":"RT-PCR, Northern blot, chemotaxis assay, mouse CCR8 cloning","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — cloning and functional characterization of mouse CCR8 ortholog, replicated pattern of Th2-selective expression across human and mouse systems","pmids":["9670926"],"is_preprint":false},{"year":1998,"finding":"CCR8 expression on Th2 cells is transiently up-regulated following TCR and CD28 engagement (activation-induced), and this up-regulation occurs independently of IL-4. Functional chemotactic responsiveness to I-309 is correspondingly enhanced upon activation.","method":"Flow cytometry, chemotaxis assay, cytokine neutralization (anti-IL-4)","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional receptor upregulation demonstrated by flow cytometry and chemotaxis in polarized primary T cell subsets, single lab","pmids":["9820476"],"is_preprint":false},{"year":1998,"finding":"CCR8 functions as a coreceptor for diverse HIV-1 strains (T-cell tropic, dual-tropic, and macrophage-tropic), and the CCR8 ligand I-309 potently inhibits HIV-1 envelope-mediated cell-cell fusion and virus infection.","method":"Cell-cell fusion assay, virus infection assay, flow cytometry, Ca2+ flux assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — functional coreceptor activity demonstrated with multiple HIV-1 strains and inhibition by endogenous ligand, replicated by additional labs (PMID:9480837, PMID:10888633, PMID:20947116)","pmids":["9417093","9480837","10888633"],"is_preprint":false},{"year":1999,"finding":"HHV-8-encoded vMIP-I is a selective CCR8 agonist: it binds CCR8 with high affinity (Kd <15 nM), induces Ca2+ signals in human T cells selectively through CCR8, and acts as agonist. By contrast, viral chemokines vMIP-II and vMCC-I act as potent CCR8 antagonists (binding without inducing signaling, blocking I-309 effects). A panel of 65 chemokines was used to establish CCR8 ligand selectivity.","method":"Calcium mobilization assay, competition binding assay with 65 chemokines, antagonism assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — comprehensive ligand binding fingerprint with large panel, replicated agonist/antagonist pharmacology confirmed by independent lab (PMID:10377196)","pmids":["10419462"],"is_preprint":false},{"year":1999,"finding":"vMIP-I (KSHV-encoded) is a specific agonist for CCR8: CCR8-transfected Y3 cells showed calcium flux and vigorous chemotaxis in response to vMIP-I, with high-affinity competitive binding, and no interaction with CCR5 or 11 other receptors tested.","method":"Calcium flux assay, in vitro chemotaxis, competition binding assay in CCR8-transfected cells","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstituted receptor function in transfected cells, independent replication of vMIP-I as CCR8 agonist across two labs","pmids":["10377196"],"is_preprint":false},{"year":2000,"finding":"MC148, encoded by the poxvirus molluscum contagiosum, is a highly selective CCR8 antagonist: it binds only CCR8 (among 16 classified human chemokine receptors), blocks I-309-induced Ca2+ signaling and chemotaxis through CCR8 without acting as agonist, and does not affect signaling of any other chemokine receptor.","method":"Competition binding with radiolabeled chemokines, calcium mobilization assay, chemotaxis assay across 16 chemokine receptors","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 1 / Strong — comprehensive receptor selectivity panel, dual calcium and chemotaxis functional validation, confirmed as selective antagonist","pmids":["10620615"],"is_preprint":false},{"year":2001,"finding":"CCR8 is expressed on human umbilical vein endothelial cells (HUVECs) and mediates endothelial cell chemotaxis induced by I-309 and vMIP-I; this chemotaxis is blocked by anti-CCR8 antibody and pertussis toxin, demonstrating Gi-coupled receptor-mediated signaling in endothelial cells.","method":"Chemotaxis assay, antibody blocking, pertussis toxin inhibition, RNA blot, immunohistochemistry","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pertussis toxin and antibody blocking provide mechanistic evidence for Gi-coupled CCR8 signaling in endothelial cells, single lab","pmids":["11133740"],"is_preprint":false},{"year":2001,"finding":"CCR8 is specifically expressed on circulating CD4+CD25+ regulatory T cells (Tregs) and mediates their chemotactic response to CCL1 and CCL22; mature dendritic cells preferentially attract Tregs by secreting CCR4 ligands CCL17 and CCL22, positioning Tregs at sites of antigen presentation.","method":"Flow cytometry, chemotaxis assay, FACS-based sorting, alloproliferative response assay","journal":"The Journal of experimental medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — chemotaxis and receptor co-expression on primary human Tregs, single lab with functional migration assay","pmids":["11560999"],"is_preprint":false},{"year":2003,"finding":"CCR8 mediates human vascular smooth muscle cell (VSMC) chemotaxis induced by CCL1 and vMIP-I via a G-protein-dependent mechanism (blocked by anti-CCR8 mAb and pertussis toxin). CCL1 also induces CCR8-dependent pro-MMP-2 mRNA and protein secretion from VSMCs, and the poxvirus CCR8 antagonist MC148 inhibited CCL1-induced MMP-2 induction, confirming CCR8 dependence.","method":"Chemotaxis assay, antibody blocking, pertussis toxin inhibition, RT-PCR, Western blot for MMP-2, MC148 antagonism","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (antibody blocking, PTX, selective antagonist, mRNA/protein) in single lab","pmids":["14576057"],"is_preprint":false},{"year":2003,"finding":"CCR8 activation by CCL1 or vMIP-I mediates rescue from dexamethasone-induced apoptosis in murine thymic lymphoma cells and primary thymocytes via ERK-dependent signaling; the selective CCR8 antagonist MC148/vMCC-I blocks this anti-apoptotic effect, formally establishing CCR8 as the receptor responsible.","method":"Apoptosis assay, ERK phosphorylation assay, MC148 antagonism, pertussis toxin inhibition","journal":"Journal of leukocyte biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mechanistic anti-apoptotic pathway defined with selective antagonist and ERK pathway inhibition, single lab","pmids":["12525579"],"is_preprint":false},{"year":2003,"finding":"CCR8 activation by CCL1 or vMIP-I activates the RAS/MAPK pathway (ERK1/2 phosphorylation) in BW5147 thymic lymphoma cells and CCR8-transfected CHO cells, mediating anti-apoptotic activity. PD98059 (MEK inhibitor) and dominant-negative M-RAS blocked CCL1 anti-apoptotic activity.","method":"ERK phosphorylation assay, CHO transfection, MEK inhibitor (PD98059), dominant-negative M-RAS expression, apoptosis assay","journal":"European journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pathway dissection with pharmacological inhibitor and dominant-negative in two cell systems, single lab","pmids":["12645948"],"is_preprint":false},{"year":2004,"finding":"Post-translational sulfation of tyrosines Y14 and Y15 in the N-terminal domain of mouse CCR8 is critical for its ligand-binding activity; Y14Y15→F14F15 double mutant showed markedly reduced sulfation and was essentially inactive for CCL1 binding and calcium flux. N-linked glycosylation at N8 and O-linked glycosylation at T10/T12 had minor effects on ligand binding.","method":"Site-directed mutagenesis (Tyr→Phe, Asn→Gln, Thr→Ala substitutions), flow cytometry with CCL1-Fc fusion, calcium flux assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — systematic mutagenesis of post-translational modification sites with functional validation by ligand binding and signaling assays, single lab with multiple orthogonal readouts","pmids":["14736884"],"is_preprint":false},{"year":2005,"finding":"LEC (CCL16) induces chemotaxis and cell adhesion by binding to and activating both CCR1 and CCR8 transfected HEK-293 cells, though at higher molar concentrations than RANTES or I-309 respectively.","method":"Chemotaxis assay, competition binding assay in CCR1- and CCR8-transfected HEK-293 cells, neutralizing antibody validation","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional binding and chemotaxis demonstrated in transfected cells with neutralizing antibody confirmation, single lab","pmids":["10910894"],"is_preprint":false},{"year":2007,"finding":"A nonpeptide CCR8 agonist LMD-009 selectively activates CCR8 among 20 human chemokine receptors, mediating chemotaxis, inositol phosphate accumulation, and calcium release (EC50 11–87 nM). Systematic mutagenesis of 25 amino acids identified Glu286 (VII:06) as a critical anchor-point (loss of potency ~1000-fold upon Ala substitution) and Phe254 (VI:16) as a gain-of-function site for LMD-009, defining the nonpeptide ligand-binding pocket.","method":"Mutagenesis of 29 positions targeting 25 residues, calcium release assay, chemotaxis assay, IP accumulation assay, 125I-CCL1 competition binding","journal":"Molecular pharmacology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — extensive mutagenesis (25 residues) with multiple functional readouts defining the molecular binding pocket of a nonpeptide agonist, single lab","pmids":["17652183"],"is_preprint":false},{"year":2006,"finding":"CCR8 receptor internalization is dependent on β-arrestins 1 and 2 but independent of Gαi signaling. The N-terminus of CCL1 plays a role in ligand binding to an intrahelical site; Glu-286 (TM helix 7) is crucial for receptor trafficking to the cell surface. CCL7 selectively antagonizes CCR8 responses to vMIP-I and partial agonist Ser-CCL1 but not to CCL1 itself, suggesting allotropic binding of CCR8 ligands at distinct sites.","method":"Calcium flux assay, chemotaxis assay, receptor internalization assay, β-arrestin KD, pertussis toxin treatment, mutagenesis (Glu-286, Asp-97), partial agonist (Ser-CCL1) synthesis","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — β-arrestin dependence shown by knockdown, allotropic binding supported by differential antagonism, mutagenesis, single lab","pmids":["17023422"],"is_preprint":false},{"year":2007,"finding":"CCL1 signaling through CCR8 on Tregs induces STAT3-dependent up-regulation of FOXP3, CD39, IL-10, and granzyme B, enhancing suppressive activity. Among four human CCR8 ligands, CCL1 is unique in potentiating Treg function. A self-feeding mechanism was identified whereby CCL1 produced by Tregs at autoimmune sites up-regulates CCR8 expression on these cells. CCR8-/- mice showed impaired Treg function in EAE adoptive transfer studies.","method":"Flow cytometry, STAT3 inhibitor studies, adoptive transfer in EAE model, CCR8-/- mice, CCL1-Ig administration","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (pharmacological, genetic KO, adoptive transfer) defining CCL1-CCR8-STAT3-FOXp3 signaling axis in Tregs","pmids":["28533380"],"is_preprint":false},{"year":2007,"finding":"CCR8 is required for CCL1-mediated macrophage aggregation and peritoneal adhesion: CCR8 is up-regulated on peritoneal macrophages by inflammatory stimuli and CCL1 itself (autocrine loop). CCL1 also up-regulates plasminogen activator inhibitor-1 mRNA in macrophages and mesothelial cells. CCR8-/- mice showed significantly reduced postoperative peritoneal adhesions.","method":"In vitro cell aggregation assay, RT-PCR, CCR8-/- mice, anti-CCL1 neutralizing antibody treatment, in vivo adhesion model","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO and antibody neutralization with in vitro and in vivo functional readouts, single lab","pmids":["17404314"],"is_preprint":false},{"year":2007,"finding":"Mast cell-derived CCL1 acts through CCR8 on CD4+ T cells to orchestrate mucosal lung inflammatory responses. CCR8 deficiency results in reduced airway hyperresponsiveness, lung inflammation, and mucus hypersecretion comparable to mast cell-deficient mice; adenoviral CCL1 delivery to mast cell-deficient mouse lungs restored these parameters, establishing a mast cell-CCL1-CCR8-T cell axis.","method":"CCR8-/- mice, mast cell-deficient mice, adenoviral gene delivery, CCL1 neutralization, airway hyperresponsiveness measurement, BALF cytokine analysis","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO, gene delivery rescue, and neutralizing antibody all convergently define the mast cell-CCL1-CCR8-T cell mechanistic axis","pmids":["17641040"],"is_preprint":false},{"year":2011,"finding":"Mouse CCL8 is a selective agonist for CCR8 but not CCR2 (distinguishing it from other MCP chemokines). CCR8 expression defines a population of highly differentiated inflammatory Th2 cells enriched for IL-5. Ccr8- and Ccl8-deficient mice had markedly less eosinophilic inflammation than wild-type mice in a chronic atopic dermatitis model. Adoptive transfer experiments established CCR8 as a key regulator of Th2 cell recruitment into allergen-inflamed skin.","method":"Calcium flux, chemotaxis assay in CCR8-transfected cells, Ccr8-/- and Ccl8-/- mouse models, adoptive transfer, flow cytometry","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — receptor usage defined in transfected cells plus genetic KO models and adoptive transfer across multiple experimental approaches","pmids":["21217759"],"is_preprint":false},{"year":2013,"finding":"Human CCR8 is a receptor for CCL18: CCL18 induced chemotaxis and calcium flux in CCR8-transfected cells, bound with high affinity, induced CCR8 internalization, and competed for CCL1 binding. CCL1 and CCL18 induced heterologous cross-desensitization of CCR8-transfected cells and human Th2 cells. Wild-type but not Ccr8-/- mouse Th2 cells migrated in response to CCL18.","method":"Chemotaxis assay, calcium flux, radiolabeled competition binding, receptor internalization, cross-desensitization assay, Ccr8-/- mice","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods including genetic KO confirmation, receptor internalization, and cross-desensitization in both transfected cells and primary cells","pmids":["23999500"],"is_preprint":false},{"year":2012,"finding":"C-terminal clipping of CCL1/I-309 by carboxypeptidase M (CPM) augments CCR8-mediated intracellular calcium release and anti-apoptotic activity while reducing direct CCL1 binding to CCR8, demonstrating that proteolytic processing modulates the CCL1-CCR8 signaling axis.","method":"In vitro enzymatic cleavage by CPM, mass spectrometry, calcium flux assay, CCR8 binding assay, apoptosis assay, carboxypeptidase inhibitor control","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro enzymatic processing with mass spectrometry verification and multiple functional assays, single lab","pmids":["22479563"],"is_preprint":false},{"year":2018,"finding":"CCR8 on CD301b+ dendritic cells (DCs) is required for their migration from the subcapsular sinus into lymph node parenchyma after allergen exposure. CCR8 ligand CCL8 is produced by CD169+SIGN-R1+ macrophages in interfollicular regions after allergen exposure and synergizes with CCL21 in a Src-kinase-dependent manner to promote DC migration. In CCR8-deficient mice, CD301b+ DCs accumulated in the subcapsular sinus and were unable to enter the LN parenchyma, resulting in defective Th2 differentiation.","method":"CCR8-/- mice, intravital microscopy/flow cytometry, Src-kinase inhibitor, in vitro migration assay, Th2 differentiation assay","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO phenotype with mechanistic pathway (CCL8→CCR8→Src-kinase→migration) defined by pharmacological inhibition and cellular analysis","pmids":["30170811"],"is_preprint":false},{"year":2019,"finding":"Activated ILC2s produce CCL1 (the CCR8 ligand) and are a major source of CCL1 in vivo; CCL1 signaling through CCR8 on ILC2s regulates their proliferation and supports their capacity to protect against helminthic infections (rather than primarily mediating ILC2 migration).","method":"In vitro CCL1 production assays, in vivo helminth infection model, CCR8-/- mice, proliferation assay","journal":"The Journal of experimental medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO with in vitro and in vivo functional readouts, single lab, distinguishes proliferative from migratory function","pmids":["31537642"],"is_preprint":false},{"year":2014,"finding":"CCR8 is required for LPS-triggered cytokine production (TNF-α, IL-6, IL-10) in peritoneal macrophages but not bone marrow-derived macrophages. CCR8-/- peritoneal macrophages showed attenuated c-Jun N-terminal kinase activity and NF-κB signaling after LPS treatment, revealing cross-talk between CCR8 and TLR-4 signaling pathways. The CCR8 antagonist R243 recapitulated CCR8-/- phenotypes.","method":"CCR8-/- mice, ELISA, CCR8 antagonist R243, JNK assay, NF-κB signaling assay, in vivo peritoneal adhesion and colitis models","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO corroborated by pharmacological antagonist, signaling pathway defined by JNK and NF-κB assays, single lab","pmids":["24714157"],"is_preprint":false},{"year":2021,"finding":"CCR8 expression on tumor-infiltrating Tregs results from TCR-mediated triggering in an NF-κB-dependent fashion. CCR8 protein is selectively prominent on highly activated, strongly suppressive tumor-infiltrating Treg subpopulations in both mouse and human tumors, with minimal CCR8-positivity on peripheral Tregs. Depletion of CCR8+ ti-Tregs by ADCC-prone anti-CCR8 nanobody-Fc in a NK-cell-dependent manner elicited antitumor immunity and reduced tumor growth; ADCC-deficient blocking antibody had no effect, indicating that Treg depletion (not CCR8 blockade) is the mechanism of antitumor activity.","method":"Single-cell RNA-seq, flow cytometry, NF-κB inhibitor, nanobody-Fc constructs with/without ADCC, NK cell depletion, syngeneic mouse tumor models (LLC-OVA, MC38)","journal":"Journal for immunotherapy of cancer","confidence":"High","confidence_rationale":"Tier 2 / Strong — NF-κB dependence of CCR8 expression tested pharmacologically, ADCC mechanism confirmed by isotype comparison and NK depletion, supported by scRNA-seq","pmids":["33589525"],"is_preprint":false},{"year":2024,"finding":"Three cryo-EM structures of human CCR8 complexed with Gi trimers were solved in the ligand-free state and activated by nonpeptide agonists LMD-009 and ZK 756326. A conserved Y1.39Y3.32E7.39 motif in the orthosteric binding pocket plays a crucial role in chemokine and nonpeptide ligand recognition. Lack of conservation in Y1143.33 and Y1724.64 among CC chemokine receptors contributes to nonpeptide ligand selectivity for CCR8.","method":"Cryo-electron microscopy, structural analysis, mutagenesis (functional validation of key residues)","journal":"Science advances","confidence":"High","confidence_rationale":"Tier 1 / Moderate — cryo-EM structures with functional mutagenesis validation, multiple structures across ligand-free and activated states, single lab","pmids":["38306437"],"is_preprint":false},{"year":2021,"finding":"CCR8-mediated signaling is biased: human CCL1 induces cell migration via Gβγ-dependent signaling, whereas other CCR8 agonists (vCCL1, ZK756326, AZ6) induce migration independently of Gβγ. All agonists were full agonists for calcium mobilization; CCR8 agonists predominantly induce Gαi-dependent cellular impedance signaling. Small molecule agonists display higher efficacy in β-arrestin 1 recruitment, occurring independently of Gαi, classifying them as biased agonists.","method":"hCCL1-AF647 binding assay, calcium mobilization, cellular impedance, chemotaxis, β-arrestin 1/2 recruitment assay, Gβγ inhibitor (gallein), Gαi inhibitor (pertussis toxin)","journal":"Biochemical pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple signaling pathway assays with pharmacological inhibitors defining biased agonism, single lab","pmids":["33872569"],"is_preprint":false},{"year":2022,"finding":"Intracellular lactate directly elevates CCR8 expression in T cells and macrophages through histone H3K18 lactylation of the CCR8 gene promoter, as demonstrated by chromatin immunoprecipitation.","method":"Chromatin immunoprecipitation (ChIP), luciferase reporter assay, RT-qPCR, Western blot, flow cytometry","journal":"Journal of experimental & clinical cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP and luciferase reporter provide direct evidence for epigenetic (lactylation) regulation of CCR8 promoter activity, single lab","pmids":["37770937"],"is_preprint":false},{"year":2022,"finding":"CCL8 from donor kidney resident macrophages promotes recipient monocyte graft infiltration via CCR8; CCR8+ T cells (CD4, CD8, γδ) infiltrate the allograft following CCL8 induction. Blocking CCL8-CCR8 or depleting donor kidney macrophages significantly inhibited early allograft immune cell infiltration and improved allograft function.","method":"Allogeneic kidney transplant mouse model, flow cytometry, CCL8-CCR8 blocking antibody, macrophage depletion","journal":"Journal of the American Society of Nephrology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo blocking and cellular depletion experiments in transplant model, single lab","pmids":["35973731"],"is_preprint":false},{"year":2019,"finding":"Disruption of the CCL1-CCR8 axis (via CCL1/Apoe double-KO mice or CCR8 blocking antibodies in LDLR-/- mice) promoted atherosclerosis, reduced plasma IL-10, increased Th1/Th2 ratio, and decreased regulatory T cell content in aorta and spleen. In vitro flow chamber assays and in vivo intravital microscopy demonstrated CCL1 mediates leukocyte recruitment to atherosclerotic vessels.","method":"Double-KO mice (Ccl1-/-/Apoe-/-), CCR8 blocking antibody in LDLR-/- mice, intravital microscopy, in vitro flow chamber, flow cytometry, ELISA","journal":"Journal of molecular and cellular cardiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic and antibody-based disruption with multiple in vivo and in vitro readouts, single lab","pmids":["31121182"],"is_preprint":false},{"year":2024,"finding":"TNF-α in the colorectal cancer microenvironment upregulates CCR8 expression in Tregs via the TNFR2/NF-κB signaling pathway and the FOXP3 transcription factor.","method":"Flow cytometry, Western blot, NF-κB pathway inhibition, TNFR2 knockout/blockade, luciferase reporter","journal":"Journal of molecular cell biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — TNFR2/NF-κB pathway defined by KO and pharmacological inhibition for CCR8 upregulation, single lab","pmids":["37935468"],"is_preprint":false},{"year":2001,"finding":"CCR8 functions as an HIV-1 coreceptor on primary human thymocytes: 125I-I-309 bound specifically to thymocyte surfaces, I-309 inhibited HIV-1 fusion with thymocytes in a dose-dependent manner, and I-309 partially inhibited productive infection by X4, R5, and X4R5 HIV-1 strains.","method":"125I-I-309 binding assay on primary thymocytes, cell-cell fusion inhibition assay, productive HIV-1 infection assay","journal":"Journal of virology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct radioligand binding and functional HIV inhibition on primary cells, single lab","pmids":["10888633"],"is_preprint":false},{"year":2018,"finding":"CCL18 promotes uptake of glycosylated extracellular vesicles (EVs) by glioblastoma cells via a triple interaction involving CCR8 on recipient cells, glycans on EVs, and CCL18 as a bridging molecule. EV-induced proliferation and temozolomide resistance are neutralized by the CCR8 small molecule inhibitor R243.","method":"RNAi screening, in vitro and in vivo glioblastoma models, CCR8 inhibitor R243, flow cytometry","journal":"Journal of extracellular vesicles","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — RNAi screen plus pharmacological inhibition identifying CCR8 in EV uptake mechanism, single lab","pmids":["29696074"],"is_preprint":false},{"year":2022,"finding":"CCL18 from microglia/macrophages promotes glioma cell growth and invasion via CCR8 as a functional receptor, with ACP5 (acid phosphatase 5) identified as an important downstream signaling component. This was validated in a humanized ex vivo slice model using iPSC-derived human microglia and in an in vivo GBM model.","method":"Humanized brain slice model (iPSC-derived human microglia), CCR8 receptor identification, ACP5 downstream signaling, in vivo GBM mouse model","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional receptor-ligand interaction validated in humanized ex vivo and in vivo models with downstream signaling component identified, single lab","pmids":["35417708"],"is_preprint":false},{"year":2021,"finding":"CCL1 from tumor-associated macrophages promotes esophageal squamous cell carcinoma cell motility via CCR8 on cancer cells through the Akt/PRAS40/mTOR pathway; PI3K/Akt inhibitors, CCR8 knockdown, and anti-CCR8 neutralizing antibody suppressed CCL1-induced effects.","method":"Neutralizing antibody, siRNA knockdown of CCR8, PI3K/Akt inhibitors, motility assay, Western blot","journal":"The American journal of pathology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pathway defined by pharmacological inhibitors and knockdown, multiple orthogonal interventions, single lab","pmids":["33460563"],"is_preprint":false},{"year":2025,"finding":"CCR8+ Tregs are specifically enriched in human decidua during first-trimester pregnancy and are required for maternal-fetal tolerance. Depletion of CCR8+ dTreg cells increased fetal loss susceptibility in an abortion-prone mouse model, and adoptive transfer of CCR8+ Tregs rescued fetal loss. CCL1 produced by decidual CD49a+ natural killer cells is the primary CCR8 ligand in this context.","method":"Single-cell transcriptomics, TCR sequencing, CCR8+ Treg depletion, adoptive transfer, flow cytometry, CCL1 ELISA","journal":"Science immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic depletion and adoptive transfer rescue formally establish CCR8+ Treg requirement for maternal-fetal tolerance, ligand source identified by scRNA-seq and protein measurement","pmids":["40249828"],"is_preprint":false}],"current_model":"CCR8 is a Gi-coupled seven-transmembrane chemokine receptor that couples to pertussis toxin-sensitive G proteins and signals through the RAS/MAPK (ERK), NF-κB, and Akt/mTOR pathways; its primary endogenous ligands are CCL1, CCL8, and CCL18, while viral chemokines vMIP-I (HHV-8), vMIP-II, and MC148 (molluscum contagiosum) act as agonist or antagonist; post-translational sulfation of N-terminal tyrosines Y14/Y15 is required for ligand binding; cryo-EM structures reveal a Y1.39Y3.32E7.39 orthosteric motif and a nonpeptide binding pocket in which Glu286 is a critical anchor; CCR8 directs Th2 cell, regulatory T cell, and dendritic cell trafficking to sites of inflammation and immune regulation, mediates anti-apoptotic signaling in thymocytes, and is selectively upregulated on tumor-infiltrating Tregs via TCR/NF-κB and TNF-α/TNFR2/NF-κB signaling and by histone H3K18 lactylation, making it a target whose depletion (via ADCC-competent antibodies) selectively eliminates tumor-resident Tregs and restores anti-tumor immunity."},"narrative":{"mechanistic_narrative":"CCR8 is a Gi-coupled seven-transmembrane chemokine receptor that directs the trafficking and function of Th2 cells, regulatory T cells, and dendritic cells in immune regulation and inflammation [PMID:9207005, PMID:9670926, PMID:11560999, PMID:30170811]. It was identified as the specific receptor for the CC chemokine I-309/CCL1, conferring calcium flux and chemotaxis in heterologous cells through a pertussis toxin-sensitive Gi protein [PMID:9207005, PMID:9211859], and additional endogenous agonists CCL8 and CCL18 were subsequently established by binding, calcium flux, and chemotaxis in transfected and Ccr8-deficient cells [PMID:21217759, PMID:23999500]. Viral chemokines define its pharmacology: HHV-8/KSHV vMIP-I acts as a selective agonist, whereas vMIP-II, vMCC-I, and the molluscum contagiosum-encoded MC148 are selective antagonists [PMID:10419462, PMID:10377196, PMID:10620615]. Ligand binding requires post-translational sulfation of N-terminal tyrosines Y14/Y15 [PMID:14736884], and cryo-EM of CCR8-Gi complexes resolved a conserved Y1.39Y3.32E7.39 orthosteric motif and the nonpeptide binding pocket anchored by Glu286 [PMID:17652183, PMID:38306437]. Downstream, CCR8 activates the RAS/ERK pathway to deliver anti-apoptotic signaling in thymocytes [PMID:12525579, PMID:12645948], couples to NF-κB/JNK in macrophages [PMID:24714157], and engages β-arrestin-dependent internalization and biased agonism [PMID:17023422, PMID:33872569]. In regulatory T cells, CCL1-CCR8-STAT3 signaling upregulates FOXP3, CD39, IL-10, and granzyme B to enhance suppression [PMID:28533380], and CCR8 is selectively induced on highly suppressive tumor-infiltrating Tregs via TCR/NF-κB and TNF-α/TNFR2/NF-κB signaling and by H3K18-lactylation of its promoter [PMID:33589525, PMID:37770937, PMID:37935468]; ADCC-competent anti-CCR8 antibodies deplete these Tregs and restore antitumor immunity [PMID:33589525]. CCR8 also serves as an HIV-1 coreceptor [PMID:9417093, PMID:9480837, PMID:10888633] and is required for CCR8+ Treg-mediated maternal-fetal tolerance [PMID:40249828].","teleology":[{"year":1997,"claim":"Established CCR8's founding identity by showing the orphan receptor CY6/TER1/CKR-L1 is the specific, Gi-coupled receptor for the CC chemokine I-309/CCL1.","evidence":"Heterologous transfection of pre-B cells with calcium flux, radioligand binding, chemotaxis, and pertussis toxin inhibition","pmids":["9207005","9211859"],"confidence":"High","gaps":["Did not define downstream effector pathways beyond Gi coupling","Physiological cell types expressing CCR8 only partially mapped (monocytes, thymus)"]},{"year":1998,"claim":"Linked CCR8 to a defined immune compartment by demonstrating selective expression on Th2-polarized T cells and activation-induced, IL-4-independent upregulation.","evidence":"RT-PCR/Northern blot, mouse CCR8 cloning, chemotaxis, flow cytometry with anti-IL-4 neutralization in polarized primary T cells","pmids":["9670926","9820476"],"confidence":"High","gaps":["Did not establish in vivo function of Th2-restricted CCR8","Ligand repertoire beyond I-309 still ambiguous at this stage"]},{"year":1998,"claim":"Identified CCR8 as an HIV-1 coreceptor whose endogenous ligand blocks viral entry, connecting the receptor to viral pathogenesis.","evidence":"Cell-cell fusion and infection assays across T-tropic, dual-tropic, and macrophage-tropic strains with I-309 inhibition; later extended to primary thymocytes","pmids":["9417093","9480837","10888633"],"confidence":"High","gaps":["Relative contribution of CCR8 versus dominant coreceptors in vivo unresolved","Structural basis of gp120-CCR8 engagement not defined"]},{"year":1999,"claim":"Defined CCR8's viral chemokine pharmacology, distinguishing agonist from antagonist ligands and establishing its ligand-binding fingerprint.","evidence":"Large-panel (65-chemokine) competition binding, calcium mobilization, chemotaxis, and antagonism assays in transfected cells; MC148 added selective antagonist","pmids":["10419462","10377196","10620615"],"confidence":"High","gaps":["Did not resolve structural determinants of agonist versus antagonist behavior","Physiological relevance of viral ligand engagement in infected hosts not addressed"]},{"year":2003,"claim":"Established the anti-apoptotic signaling output of CCR8 by mapping CCL1/vMIP-I activation to the RAS/MEK/ERK cascade in thymocytes.","evidence":"ERK phosphorylation, MEK inhibitor (PD98059), dominant-negative M-RAS, MC148 antagonism, and apoptosis assays in thymic lymphoma and CHO cells","pmids":["12525579","12645948"],"confidence":"Medium","gaps":["Single-lab pathway dissection","In vivo relevance of thymocyte survival signaling not tested"]},{"year":2004,"claim":"Identified the post-translational requirement for ligand binding by showing N-terminal tyrosine sulfation (Y14/Y15) is essential for CCL1 recognition.","evidence":"Site-directed mutagenesis (Tyr→Phe, glycosylation-site mutants) with CCL1-Fc binding and calcium flux readouts on mouse CCR8","pmids":["14736884"],"confidence":"High","gaps":["Sulfotransferase responsible not identified","Generalization to human CCR8 ligands beyond CCL1 not tested in this study"]},{"year":2007,"claim":"Defined the nonpeptide ligand-binding pocket and established CCR8's role in Treg suppressive programming via CCL1-STAT3-FOXP3 signaling.","evidence":"Extensive mutagenesis (25 residues) identifying Glu286 anchor; separately STAT3 inhibitor studies, CCR8-/- mice, and CCL1-Ig administration in EAE","pmids":["17652183","28533380"],"confidence":"High","gaps":["Mechanism linking Glu286 to receptor trafficking versus binding only partially separated","STAT3-FOXP3 axis tested largely in autoimmune, not tumor, context at this stage"]},{"year":2006,"claim":"Resolved the trafficking and biased-signaling logic of CCR8 by showing β-arrestin-dependent internalization separable from Gi signaling and allotropic ligand binding sites.","evidence":"β-arrestin knockdown, internalization assays, Glu286/Asp97 mutagenesis, partial agonist Ser-CCL1, and differential CCL7 antagonism; later extended to biased agonism profiling","pmids":["17023422","33872569"],"confidence":"Medium","gaps":["Functional consequences of biased agonism in vivo undefined","Single-lab arrestin dependence without reciprocal genetic confirmation"]},{"year":2011,"claim":"Expanded the endogenous ligand set and tissue function by establishing CCL8 (and later CCL18) as selective CCR8 agonists driving Th2 recruitment in allergic inflammation.","evidence":"Calcium flux/chemotaxis in transfected cells, Ccr8-/- and Ccl8-/- mice, adoptive transfer in atopic dermatitis and cross-desensitization with Ccr8-/- Th2 cells","pmids":["21217759","23999500"],"confidence":"High","gaps":["Hierarchy among CCL1/CCL8/CCL18 in distinct tissues not fully resolved","Species differences in CCL8/CCR8 usage incompletely mapped"]},{"year":2018,"claim":"Defined CCR8's role in dendritic cell positioning by showing CCL8-CCR8-Src signaling is required for CD301b+ DC migration into lymph node parenchyma and downstream Th2 differentiation.","evidence":"CCR8-/- mice, intravital imaging, Src-kinase inhibition, and in vitro migration with CCL8/CCL21 synergy","pmids":["30170811"],"confidence":"High","gaps":["Mechanism of CCL8/CCL21 synergy at the receptor level not defined","Whether this DC axis operates outside allergen contexts unknown"]},{"year":2021,"claim":"Established CCR8 as a therapeutic target on tumor-infiltrating Tregs, showing TCR/NF-κB-driven selective expression and ADCC-dependent (not blockade-dependent) Treg depletion as the antitumor mechanism.","evidence":"scRNA-seq, NF-κB inhibitor, ADCC-competent versus ADCC-deficient nanobody-Fc, NK depletion, syngeneic tumor models; epigenetic and TNFR2 routes added later","pmids":["33589525","37770937","37935468"],"confidence":"High","gaps":["Whether CCR8 has an intrinsic functional role in ti-Treg suppression versus being a depletion marker not fully separated","Lactylation and TNFR2 mechanisms shown in single labs"]},{"year":2024,"claim":"Provided the structural framework for CCR8 ligand recognition and selectivity by resolving cryo-EM structures of CCR8-Gi complexes in ligand-free and agonist-bound states.","evidence":"Cryo-EM of CCR8-Gi with nonpeptide agonists LMD-009 and ZK 756326, plus functional mutagenesis of the Y1.39Y3.32E7.39 motif","pmids":["38306437"],"confidence":"High","gaps":["No structure with endogenous chemokine ligand bound","Conformational basis of biased agonism not captured"]},{"year":2025,"claim":"Extended CCR8's regulatory T cell function to reproductive immunology by establishing CCR8+ decidual Tregs as required for maternal-fetal tolerance.","evidence":"Single-cell transcriptomics, TCR sequencing, CCR8+ Treg depletion and adoptive-transfer rescue in an abortion-prone mouse model, with decidual NK-derived CCL1 identified","pmids":["40249828"],"confidence":"High","gaps":["Signaling output of CCR8 in decidual Tregs not dissected","Human causal evidence limited to enrichment/correlation"]},{"year":null,"claim":"It remains unresolved whether CCR8 signaling is intrinsically required for tumor-infiltrating Treg suppressive function, or whether CCR8 is principally a depletion-enabling surface marker, and how biased/allotropic ligand engagement translates into distinct in vivo outcomes.","evidence":"","pmids":[],"confidence":"High","gaps":["No genetic separation of CCR8 signaling from CCR8 expression in ti-Tregs","Structural basis of biased agonism with endogenous ligands undefined","Tissue-specific ligand hierarchy (CCL1/CCL8/CCL18) not resolved"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,1,6,7,8]},{"term_id":"GO:0001618","term_label":"virus receptor activity","supporting_discovery_ids":[5,34]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,14,17,28]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,13,29]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[3,18,24,27]},{"term_id":"R-HSA-1500931","term_label":"Cell-Cell communication","supporting_discovery_ids":[10,21,24]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[5,27,37]}],"complexes":[],"partners":["CCL1","CCL8","CCL18","GNAI1","ARRB1","ARRB2"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P51685","full_name":"C-C chemokine receptor type 8","aliases":["CC chemokine receptor CHEMR1","CMKBRL2","Chemokine receptor-like 1","CKR-L1","GPR-CY6","GPRCY6","TER1"],"length_aa":355,"mass_kda":40.8,"function":"G protein-coupled receptor that can bind a variety of chemokines, such as CCL1, CCL8, CCL16, CCL18 (PubMed:23999500, PubMed:35041514). Regulates monocyte and eosinophil chemotaxis. Undergoes internalization upon CCL18 binding, leading to induced migration and calcium flux of highly polarized Th2 cells (PubMed:23999500). In microglial cells, promotes phagocytosis with CCL18 through NF-kappa-B and Src signaling pathways (PubMed:35041514). Stimulation of the CCL1-CCR8 signaling axis protects the gut from acute intestinal damage (By similarity) (Microbial infection) Acts as a coreceptor for HIV-1 and HIV-2 viruses (Microbial infection) Acts as a receptor for Kaposi virus protein vCCL1/K6 and thereby inhibits apoptosis in the targeted cells","subcellular_location":"Cell membrane","url":"https://www.uniprot.org/uniprotkb/P51685/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CCR8","classification":"Not Classified","n_dependent_lines":2,"n_total_lines":1208,"dependency_fraction":0.0016556291390728477},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CCR8","total_profiled":1310},"omim":[{"mim_id":"605699","title":"UL16-BINDING PROTEIN 3; ULBP3","url":"https://www.omim.org/entry/605699"},{"mim_id":"605698","title":"UL16-BINDING PROTEIN 2; ULBP2","url":"https://www.omim.org/entry/605698"},{"mim_id":"605697","title":"UL16-BINDING PROTEIN 1; ULBP1","url":"https://www.omim.org/entry/605697"},{"mim_id":"603757","title":"CHEMOKINE, CC MOTIF, LIGAND 18; CCL18","url":"https://www.omim.org/entry/603757"},{"mim_id":"601834","title":"CHEMOKINE, CC MOTIF, RECEPTOR 8; CCR8","url":"https://www.omim.org/entry/601834"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"lymphoid tissue","ntpm":7.2}],"url":"https://www.proteinatlas.org/search/CCR8"},"hgnc":{"alias_symbol":["CY6","TER1","CKR-L1","GPR-CY6","CDw198"],"prev_symbol":["CMKBRL2","CMKBR8"]},"alphafold":{"accession":"P51685","domains":[{"cath_id":"1.20.1070.10","chopping":"38-311","consensus_level":"high","plddt":91.4957,"start":38,"end":311}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P51685","model_url":"https://alphafold.ebi.ac.uk/files/AF-P51685-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P51685-F1-predicted_aligned_error_v6.png","plddt_mean":82.12},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CCR8","jax_strain_url":"https://www.jax.org/strain/search?query=CCR8"},"sequence":{"accession":"P51685","fasta_url":"https://rest.uniprot.org/uniprotkb/P51685.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P51685/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P51685"}},"corpus_meta":[{"pmid":"11560999","id":"PMC_11560999","title":"Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4(+)CD25(+) regulatory T cells.","date":"2001","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/11560999","citation_count":713,"is_preprint":false},{"pmid":"9820476","id":"PMC_9820476","title":"Selective up-regulation of chemokine receptors CCR4 and CCR8 upon activation of polarized human type 2 Th cells.","date":"1998","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/9820476","citation_count":346,"is_preprint":false},{"pmid":"11390417","id":"PMC_11390417","title":"The C-C chemokine receptors CCR4 and CCR8 identify airway T cells of allergen-challenged atopic asthmatics.","date":"2001","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/11390417","citation_count":333,"is_preprint":false},{"pmid":"9670926","id":"PMC_9670926","title":"The chemokine receptor CCR8 is preferentially expressed in Th2 but not Th1 cells.","date":"1998","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/9670926","citation_count":329,"is_preprint":false},{"pmid":"33076281","id":"PMC_33076281","title":"CC Chemokines in a Tumor: A Review of Pro-Cancer and Anti-Cancer Properties of Receptors CCR5, CCR6, CCR7, CCR8, CCR9, and CCR10 Ligands.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33076281","citation_count":308,"is_preprint":false},{"pmid":"21217759","id":"PMC_21217759","title":"Mouse CCL8, a CCR8 agonist, promotes atopic dermatitis by recruiting IL-5+ T(H)2 cells.","date":"2011","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/21217759","citation_count":261,"is_preprint":false},{"pmid":"28533380","id":"PMC_28533380","title":"CCR8+FOXp3+ Treg cells as master drivers of immune regulation.","date":"2017","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/28533380","citation_count":196,"is_preprint":false},{"pmid":"9207005","id":"PMC_9207005","title":"Identification of CCR8: a human monocyte and thymus receptor for the CC chemokine I-309.","date":"1997","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/9207005","citation_count":179,"is_preprint":false},{"pmid":"15814739","id":"PMC_15814739","title":"CCL1-CCR8 interactions: an axis mediating the recruitment of T cells and Langerhans-type dendritic cells to sites of atopic skin inflammation.","date":"2005","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/15814739","citation_count":174,"is_preprint":false},{"pmid":"33589525","id":"PMC_33589525","title":"Therapeutic depletion of CCR8+ tumor-infiltrating regulatory T cells elicits antitumor immunity and synergizes with anti-PD-1 therapy.","date":"2021","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/33589525","citation_count":168,"is_preprint":false},{"pmid":"23999500","id":"PMC_23999500","title":"Identification of human CCR8 as a CCL18 receptor.","date":"2013","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/23999500","citation_count":158,"is_preprint":false},{"pmid":"35140181","id":"PMC_35140181","title":"CCR8-targeted specific depletion of clonally expanded Treg cells in tumor tissues evokes potent tumor immunity with long-lasting memory.","date":"2022","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/35140181","citation_count":156,"is_preprint":false},{"pmid":"10419462","id":"PMC_10419462","title":"HHV8-encoded vMIP-I selectively engages chemokine receptor CCR8. Agonist and antagonist profiles of viral chemokines.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10419462","citation_count":148,"is_preprint":false},{"pmid":"9211859","id":"PMC_9211859","title":"Identification of CCR8, the receptor for the human CC chemokine I-309.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9211859","citation_count":147,"is_preprint":false},{"pmid":"9417093","id":"PMC_9417093","title":"The CC chemokine I-309 inhibits CCR8-dependent infection by diverse HIV-1 strains.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9417093","citation_count":143,"is_preprint":false},{"pmid":"37770937","id":"PMC_37770937","title":"Oxamate enhances the efficacy of CAR-T therapy against glioblastoma via suppressing ectonucleotidases and CCR8 lactylation.","date":"2023","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/37770937","citation_count":136,"is_preprint":false},{"pmid":"10377196","id":"PMC_10377196","title":"The Kaposi's sarcoma-related herpesvirus (KSHV)-encoded chemokine vMIP-I is a specific agonist for the CC chemokine receptor (CCR)8.","date":"1999","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/10377196","citation_count":117,"is_preprint":false},{"pmid":"17082609","id":"PMC_17082609","title":"CCR8 expression identifies CD4 memory T cells enriched for FOXP3+ regulatory and Th2 effector lymphocytes.","date":"2006","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/17082609","citation_count":115,"is_preprint":false},{"pmid":"10620615","id":"PMC_10620615","title":"A highly selective CC chemokine receptor (CCR)8 antagonist encoded by the poxvirus molluscum contagiosum.","date":"2000","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/10620615","citation_count":108,"is_preprint":false},{"pmid":"30026324","id":"PMC_30026324","title":"Targeting CCR8 Induces Protective Antitumor Immunity and Enhances Vaccine-Induced Responses in Colon Cancer.","date":"2018","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/30026324","citation_count":107,"is_preprint":false},{"pmid":"19062085","id":"PMC_19062085","title":"Contribution of CCR4 and CCR8 to antigen-specific T(H)2 cell trafficking in allergic pulmonary inflammation.","date":"2008","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/19062085","citation_count":105,"is_preprint":false},{"pmid":"18157152","id":"PMC_18157152","title":"TER1, the RNA subunit of fission yeast telomerase.","date":"2007","source":"Nature structural & molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/18157152","citation_count":101,"is_preprint":false},{"pmid":"33757978","id":"PMC_33757978","title":"Fc-Optimized Anti-CCR8 Antibody Depletes Regulatory T Cells in Human Tumor Models.","date":"2021","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/33757978","citation_count":100,"is_preprint":false},{"pmid":"30170811","id":"PMC_30170811","title":"The Chemokine Receptor CCR8 Promotes the Migration of Dendritic Cells into the Lymph Node Parenchyma to Initiate the Allergic Immune Response.","date":"2018","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/30170811","citation_count":99,"is_preprint":false},{"pmid":"18157149","id":"PMC_18157149","title":"Identification and characterization of the Schizosaccharomyces pombe TER1 telomerase RNA.","date":"2007","source":"Nature structural & molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/18157149","citation_count":96,"is_preprint":false},{"pmid":"9521068","id":"PMC_9521068","title":"Identification of the CC chemokines TARC and macrophage inflammatory protein-1 beta as novel functional ligands for the CCR8 receptor.","date":"1998","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9521068","citation_count":91,"is_preprint":false},{"pmid":"12496446","id":"PMC_12496446","title":"CCR8 is not essential for the development of inflammation in a mouse model of allergic airway disease.","date":"2003","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/12496446","citation_count":83,"is_preprint":false},{"pmid":"29696074","id":"PMC_29696074","title":"Glycosylated extracellular vesicles released by glioblastoma cells are decorated by CCL18 allowing for cellular uptake via chemokine receptor CCR8.","date":"2018","source":"Journal of extracellular vesicles","url":"https://pubmed.ncbi.nlm.nih.gov/29696074","citation_count":80,"is_preprint":false},{"pmid":"35428909","id":"PMC_35428909","title":"Tumor-derived exosomes drive pre-metastatic niche formation in lung via modulating CCL1+ fibroblast and CCR8+ Treg cell interactions.","date":"2022","source":"Cancer immunology, immunotherapy : CII","url":"https://pubmed.ncbi.nlm.nih.gov/35428909","citation_count":78,"is_preprint":false},{"pmid":"12574386","id":"PMC_12574386","title":"Absence of CCR8 does not impair the response to ovalbumin-induced allergic airway disease.","date":"2003","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/12574386","citation_count":77,"is_preprint":false},{"pmid":"29427415","id":"PMC_29427415","title":"CCR8 Expression Defines Tissue-Resident Memory T Cells in Human Skin.","date":"2018","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/29427415","citation_count":76,"is_preprint":false},{"pmid":"9480837","id":"PMC_9480837","title":"Identification of the chemokine receptor TER1/CCR8 expressed in brain-derived cells and T cells as a new coreceptor for HIV-1 infection.","date":"1998","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/9480837","citation_count":75,"is_preprint":false},{"pmid":"33838058","id":"PMC_33838058","title":"CCR8 marks highly suppressive Treg cells within tumours but is dispensable for their accumulation and suppressive function.","date":"2021","source":"Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33838058","citation_count":74,"is_preprint":false},{"pmid":"11133740","id":"PMC_11133740","title":"The chemokine receptor CCR8 mediates human endothelial cell chemotaxis induced by I-309 and Kaposi sarcoma herpesvirus-encoded vMIP-I and by lipoprotein(a)-stimulated endothelial cell conditioned medium.","date":"2001","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/11133740","citation_count":72,"is_preprint":false},{"pmid":"9469461","id":"PMC_9469461","title":"Identification of CCR8 as the specific receptor for the human beta-chemokine I-309: cloning and molecular characterization of murine CCR8 as the receptor for TCA-3.","date":"1998","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/9469461","citation_count":65,"is_preprint":false},{"pmid":"17947648","id":"PMC_17947648","title":"Recruitment and activation of macrophages by pathogenic CD4 T cells in type 1 diabetes: evidence for involvement of CCR8 and CCL1.","date":"2007","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/17947648","citation_count":64,"is_preprint":false},{"pmid":"14576057","id":"PMC_14576057","title":"Chemokine receptor-8 (CCR8) mediates human vascular smooth muscle cell chemotaxis and metalloproteinase-2 secretion.","date":"2003","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/14576057","citation_count":61,"is_preprint":false},{"pmid":"31537642","id":"PMC_31537642","title":"A CCL1/CCR8-dependent feed-forward mechanism drives ILC2 functions in type 2-mediated inflammation.","date":"2019","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31537642","citation_count":60,"is_preprint":false},{"pmid":"15699124","id":"PMC_15699124","title":"CCR8 is expressed by antigen-elicited, IL-10-producing CD4+CD25+ T cells, which regulate Th2-mediated granuloma formation in mice.","date":"2005","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/15699124","citation_count":58,"is_preprint":false},{"pmid":"17404314","id":"PMC_17404314","title":"Inhibition of CCL1-CCR8 interaction prevents aggregation of macrophages and development of peritoneal adhesions.","date":"2007","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/17404314","citation_count":56,"is_preprint":false},{"pmid":"23363815","id":"PMC_23363815","title":"Expansion of CCR8(+) inflammatory myeloid cells in cancer patients with urothelial and renal carcinomas.","date":"2013","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/23363815","citation_count":56,"is_preprint":false},{"pmid":"17641040","id":"PMC_17641040","title":"Coordinated involvement of mast cells and T cells in allergic mucosal inflammation: critical role of the CC chemokine ligand 1:CCR8 axis.","date":"2007","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/17641040","citation_count":56,"is_preprint":false},{"pmid":"8816377","id":"PMC_8816377","title":"Molecular cloning of TER1, a chemokine receptor-like gene expressed by lymphoid tissues.","date":"1996","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/8816377","citation_count":53,"is_preprint":false},{"pmid":"12645948","id":"PMC_12645948","title":"CCR8-dependent activation of the RAS/MAPK pathway mediates anti-apoptotic activity of I-309/ CCL1 and vMIP-I.","date":"2003","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12645948","citation_count":48,"is_preprint":false},{"pmid":"16195226","id":"PMC_16195226","title":"Sap1p binds to Ter1 at the ribosomal DNA of Schizosaccharomyces pombe and causes polar replication fork arrest.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16195226","citation_count":47,"is_preprint":false},{"pmid":"17652183","id":"PMC_17652183","title":"Molecular interaction of a potent nonpeptide agonist with the chemokine receptor CCR8.","date":"2007","source":"Molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/17652183","citation_count":47,"is_preprint":false},{"pmid":"23811304","id":"PMC_23811304","title":"Possible involvement of CCL1-CCR8 interaction in lymphocytic recruitment in IgG4-related sclerosing cholangitis.","date":"2013","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/23811304","citation_count":47,"is_preprint":false},{"pmid":"30592282","id":"PMC_30592282","title":"CCL18 enhances migration, invasion and EMT by binding CCR8 in bladder cancer cells.","date":"2018","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/30592282","citation_count":46,"is_preprint":false},{"pmid":"12050188","id":"PMC_12050188","title":"Increased responsiveness of murine eosinophils to MIP-1beta (CCL4) and TCA-3 (CCL1) is mediated by their specific receptors, CCR5 and CCR8.","date":"2002","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/12050188","citation_count":46,"is_preprint":false},{"pmid":"32367308","id":"PMC_32367308","title":"CCR8 blockade primes anti-tumor immunity through intratumoral regulatory T cells destabilization in muscle-invasive bladder cancer.","date":"2020","source":"Cancer immunology, immunotherapy : CII","url":"https://pubmed.ncbi.nlm.nih.gov/32367308","citation_count":45,"is_preprint":false},{"pmid":"10888633","id":"PMC_10888633","title":"CCR8 on human thymocytes functions as a human immunodeficiency virus type 1 coreceptor.","date":"2000","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/10888633","citation_count":44,"is_preprint":false},{"pmid":"35354899","id":"PMC_35354899","title":"The impact of CCR8+ regulatory T cells on cytotoxic T cell function in human lung cancer.","date":"2022","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/35354899","citation_count":42,"is_preprint":false},{"pmid":"10910894","id":"PMC_10910894","title":"LEC induces chemotaxis and adhesion by interacting with CCR1 and CCR8.","date":"2000","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/10910894","citation_count":41,"is_preprint":false},{"pmid":"31121182","id":"PMC_31121182","title":"Disruption of the CCL1-CCR8 axis inhibits vascular Treg recruitment and function and promotes atherosclerosis in mice.","date":"2019","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/31121182","citation_count":40,"is_preprint":false},{"pmid":"17181556","id":"PMC_17181556","title":"CCR7, CCR8, CCR9 and CCR10 in the mouse hippocampal CA1 area and the dentate gyrus during and after pilocarpine-induced status epilepticus.","date":"2007","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17181556","citation_count":39,"is_preprint":false},{"pmid":"36352891","id":"PMC_36352891","title":"Differential expression of CCR8 in tumors versus normal tissue allows specific depletion of tumor-infiltrating T regulatory cells by GS-1811, a novel Fc-optimized anti-CCR8 antibody.","date":"2022","source":"Oncoimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/36352891","citation_count":38,"is_preprint":false},{"pmid":"12525579","id":"PMC_12525579","title":"The chemokine receptor CCR8 mediates rescue from dexamethasone-induced apoptosis via an ERK-dependent pathway.","date":"2003","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/12525579","citation_count":38,"is_preprint":false},{"pmid":"28961489","id":"PMC_28961489","title":"Spinal CCL1/CCR8 signaling interplay as a potential therapeutic target - Evidence from a mouse diabetic neuropathy model.","date":"2017","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/28961489","citation_count":37,"is_preprint":false},{"pmid":"22215813","id":"PMC_22215813","title":"Schizosaccharomyces pombe Ccq1 and TER1 bind the 14-3-3-like domain of Est1, which promotes and stabilizes telomerase-telomere association.","date":"2012","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/22215813","citation_count":36,"is_preprint":false},{"pmid":"14736884","id":"PMC_14736884","title":"Analysis of post-translational CCR8 modifications and their influence on receptor activity.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/14736884","citation_count":36,"is_preprint":false},{"pmid":"24714157","id":"PMC_24714157","title":"Chemokine receptor CCR8 is required for lipopolysaccharide-triggered cytokine production in mouse peritoneal macrophages.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24714157","citation_count":35,"is_preprint":false},{"pmid":"34025655","id":"PMC_34025655","title":"Immunomodulation of T Helper Cells by Tumor Microenvironment in Oral Cancer Is Associated With CCR8 Expression and Rapid Membrane Vitamin D Signaling Pathway.","date":"2021","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34025655","citation_count":34,"is_preprint":false},{"pmid":"20455898","id":"PMC_20455898","title":"Expression of CCR8 is increased in asthma.","date":"2010","source":"Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/20455898","citation_count":34,"is_preprint":false},{"pmid":"20947116","id":"PMC_20947116","title":"Coreceptor usage by HIV-1 and HIV-2 primary isolates: the relevance of CCR8 chemokine receptor as an alternative coreceptor.","date":"2010","source":"Virology","url":"https://pubmed.ncbi.nlm.nih.gov/20947116","citation_count":34,"is_preprint":false},{"pmid":"16640325","id":"PMC_16640325","title":"Design, synthesis, and progress toward optimization of potent small molecule antagonists of CC chemokine receptor 8 (CCR8).","date":"2006","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16640325","citation_count":33,"is_preprint":false},{"pmid":"37935468","id":"PMC_37935468","title":"Blockade of TNF-α/TNFR2 signalling suppresses colorectal cancer and enhances the efficacy of anti-PD1 immunotherapy by decreasing CCR8+T regulatory cells.","date":"2024","source":"Journal of molecular cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/37935468","citation_count":32,"is_preprint":false},{"pmid":"35417708","id":"PMC_35417708","title":"Microglia/macrophage-derived human CCL18 promotes glioma progression via CCR8-ACP5 axis analyzed in humanized slice model.","date":"2022","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/35417708","citation_count":31,"is_preprint":false},{"pmid":"17023422","id":"PMC_17023422","title":"Structure/function relationships of CCR8 agonists and antagonists. Amino-terminal extension of CCL1 by a single amino acid generates a partial agonist.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17023422","citation_count":31,"is_preprint":false},{"pmid":"35158783","id":"PMC_35158783","title":"Chemokine Receptor-Targeted Therapies: Special Case for CCR8.","date":"2022","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/35158783","citation_count":29,"is_preprint":false},{"pmid":"16221874","id":"PMC_16221874","title":"Identification and characterization of a potent, selective nonpeptide agonist of the CC chemokine receptor CCR8.","date":"2005","source":"Molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/16221874","citation_count":28,"is_preprint":false},{"pmid":"39890548","id":"PMC_39890548","title":"CCR8: a promising therapeutic target against tumor-infiltrating regulatory T cells.","date":"2025","source":"Trends in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/39890548","citation_count":27,"is_preprint":false},{"pmid":"39080766","id":"PMC_39080766","title":"Targeting tumor-infiltrating CCR8+ regulatory T cells induces antitumor immunity through functional restoration of CD4+ Tconvs and CD8+ T cells in colorectal cancer.","date":"2024","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39080766","citation_count":26,"is_preprint":false},{"pmid":"37420296","id":"PMC_37420296","title":"S-531011, a Novel Anti-Human CCR8 Antibody, Induces Potent Antitumor Responses through Depletion of Tumor-Infiltrating CCR8-Expressing Regulatory T Cells.","date":"2023","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/37420296","citation_count":25,"is_preprint":false},{"pmid":"40249828","id":"PMC_40249828","title":"CCR8+ decidual regulatory T cells maintain maternal-fetal immune tolerance during early pregnancy.","date":"2025","source":"Science immunology","url":"https://pubmed.ncbi.nlm.nih.gov/40249828","citation_count":22,"is_preprint":false},{"pmid":"40056978","id":"PMC_40056978","title":"Selective Depletion of CCR8+Treg Cells Enhances the Antitumor Immunity of Cytotoxic T Cells in Lung Cancer by Dendritic Cells.","date":"2025","source":"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/40056978","citation_count":21,"is_preprint":false},{"pmid":"35973731","id":"PMC_35973731","title":"Blocking CCL8-CCR8-Mediated Early Allograft Inflammation Improves Kidney Transplant Function.","date":"2022","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/35973731","citation_count":21,"is_preprint":false},{"pmid":"12551893","id":"PMC_12551893","title":"Genomic organization and evolution of the CX3CR1/CCR8 chemokine receptor locus.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12551893","citation_count":21,"is_preprint":false},{"pmid":"33460563","id":"PMC_33460563","title":"Chemokine (C-C Motif) Ligand 1 Derived from Tumor-Associated Macrophages Contributes to Esophageal Squamous Cell Carcinoma Progression via CCR8-Mediated Akt/Proline-Rich Akt Substrate of 40 kDa/Mammalian Target of Rapamycin Pathway.","date":"2021","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/33460563","citation_count":20,"is_preprint":false},{"pmid":"22209712","id":"PMC_22209712","title":"Orally bioavailable allosteric CCR8 antagonists inhibit dendritic cell, T cell and eosinophil migration.","date":"2011","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/22209712","citation_count":20,"is_preprint":false},{"pmid":"36988587","id":"PMC_36988587","title":"Discovery of a Potent and Selective CCR8 Small Molecular Antagonist IPG7236 for the Treatment of Cancer.","date":"2023","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/36988587","citation_count":20,"is_preprint":false},{"pmid":"15075267","id":"PMC_15075267","title":"Genetic dissection of the Kluyveromyces lactis telomere and evidence for telomere capping defects in TER1 mutants with long telomeres.","date":"2004","source":"Eukaryotic cell","url":"https://pubmed.ncbi.nlm.nih.gov/15075267","citation_count":20,"is_preprint":false},{"pmid":"22479563","id":"PMC_22479563","title":"C-terminal clipping of chemokine CCL1/I-309 enhances CCR8-mediated intracellular calcium release and anti-apoptotic activity.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22479563","citation_count":20,"is_preprint":false},{"pmid":"17693327","id":"PMC_17693327","title":"Combination of 17beta-estradiol with the environmental pollutant TCDD is involved in pathogenesis of endometriosis via up-regulating the chemokine I-309-CCR8.","date":"2007","source":"Fertility and sterility","url":"https://pubmed.ncbi.nlm.nih.gov/17693327","citation_count":20,"is_preprint":false},{"pmid":"17850582","id":"PMC_17850582","title":"Expression of chemokine receptors CCR7 and CCR8 in the CNS during ChREAE.","date":"2007","source":"Scandinavian journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/17850582","citation_count":19,"is_preprint":false},{"pmid":"37350632","id":"PMC_37350632","title":"Immunotherapy Targeting CCR8+ Regulatory T Cells Induces Antitumor Effects via Dramatic Changes to the Intratumor CD8+ T Cell Profile.","date":"2023","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/37350632","citation_count":18,"is_preprint":false},{"pmid":"21976223","id":"PMC_21976223","title":"CCR8 signaling influences Toll-like receptor 4 responses in human macrophages in inflammatory diseases.","date":"2011","source":"Clinical and vaccine immunology : CVI","url":"https://pubmed.ncbi.nlm.nih.gov/21976223","citation_count":17,"is_preprint":false},{"pmid":"38856863","id":"PMC_38856863","title":"Selective depletion of tumor-infiltrating regulatory T cells with BAY 3375968, a novel Fc-optimized anti-CCR8 antibody.","date":"2024","source":"Clinical and experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38856863","citation_count":16,"is_preprint":false},{"pmid":"35377236","id":"PMC_35377236","title":"C8Mab-3: An Anti-Mouse CCR8 Monoclonal Antibody for Immunocytochemistry.","date":"2022","source":"Monoclonal antibodies in immunodiagnosis and immunotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/35377236","citation_count":16,"is_preprint":false},{"pmid":"31270368","id":"PMC_31270368","title":"CCR8 leads to eosinophil migration and regulates neutrophil migration in murine allergic enteritis.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/31270368","citation_count":16,"is_preprint":false},{"pmid":"25344933","id":"PMC_25344933","title":"CCR8 regulates contact hypersensitivity by restricting cutaneous dendritic cell migration to the draining lymph nodes.","date":"2014","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/25344933","citation_count":16,"is_preprint":false},{"pmid":"35483056","id":"PMC_35483056","title":"Development of an Anti-Mouse CCR8 Monoclonal Antibody (C8Mab-1) for Flow Cytometry and Immunocytochemistry.","date":"2022","source":"Monoclonal antibodies in immunodiagnosis and immunotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/35483056","citation_count":16,"is_preprint":false},{"pmid":"31121204","id":"PMC_31121204","title":"Spinal CCL1/CCR8 regulates phosphorylation of GluA1-containing AMPA receptor in postoperative pain after tibial fracture and orthopedic surgery in mice.","date":"2019","source":"Neuroscience research","url":"https://pubmed.ncbi.nlm.nih.gov/31121204","citation_count":16,"is_preprint":false},{"pmid":"11493620","id":"PMC_11493620","title":"MC148 encoded by human molluscum contagiosum poxvirus is an antagonist for human but not murine CCR8.","date":"2001","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/11493620","citation_count":16,"is_preprint":false},{"pmid":"37950246","id":"PMC_37950246","title":"CD4+CCR8+ Tregs in ovarian cancer: a potential effector Tregs for immune regulation.","date":"2023","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/37950246","citation_count":15,"is_preprint":false},{"pmid":"35377281","id":"PMC_35377281","title":"TGF-β-induced CCR8 promoted macrophage transdifferentiation into myofibroblast-like cells.","date":"2022","source":"Experimental lung research","url":"https://pubmed.ncbi.nlm.nih.gov/35377281","citation_count":15,"is_preprint":false},{"pmid":"38306437","id":"PMC_38306437","title":"Unveiling the structural mechanisms of nonpeptide ligand recognition and activation in human chemokine receptor CCR8.","date":"2024","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/38306437","citation_count":15,"is_preprint":false},{"pmid":"22708643","id":"PMC_22708643","title":"Molecular requirements for inhibition of the chemokine receptor CCR8--probe-dependent allosteric interactions.","date":"2012","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/22708643","citation_count":15,"is_preprint":false},{"pmid":"17321573","id":"PMC_17321573","title":"Remission of chronic fungal asthma in the absence of CCR8.","date":"2007","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/17321573","citation_count":15,"is_preprint":false},{"pmid":"25617117","id":"PMC_25617117","title":"In silico characterization of binding mode of CCR8 inhibitor: homology modeling, docking and membrane based MD simulation study.","date":"2015","source":"Journal of biomolecular structure & dynamics","url":"https://pubmed.ncbi.nlm.nih.gov/25617117","citation_count":14,"is_preprint":false},{"pmid":"33872569","id":"PMC_33872569","title":"Biological characterization of ligands targeting the human CC chemokine receptor 8 (CCR8) reveals the biased signaling properties of small molecule agonists.","date":"2021","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/33872569","citation_count":14,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":52661,"output_tokens":10278,"usd":0.156077,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":20859,"output_tokens":4796,"usd":0.112098,"stage2_stop_reason":"end_turn"},"total_usd":0.268175,"stage1_batch_id":"msgbatch_01ACAxJQabDsht39JXeWG22d","stage2_batch_id":"msgbatch_01QEU22A9U5sbPTgsMzTmvSf","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1997,\n      \"finding\": \"CCR8 (then named CY6/TER1/CKR-L1) was identified as the specific receptor for the human CC chemokine I-309 (CCL1). Transfection of the CY6 open reading frame into mouse pre-B cells conferred calcium flux and chemotaxis in response to I-309 (EC50 = 2 nM), while 20 other chemokines were inactive. Signaling was sensitive to pertussis toxin, indicating coupling to a Gi-type G protein. CCR8 is constitutively expressed in monocytes and thymus.\",\n      \"method\": \"Transfection of pre-B cell line, calcium flux assay, chemotaxis assay, pertussis toxin inhibition\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstituted receptor function in heterologous cells, confirmed by two independent labs (PMID:9207005 and PMID:9211859) with in vitro assays and mutagenesis-equivalent controls\",\n      \"pmids\": [\"9207005\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"CCR8 (TER1/ChemR1/CKR-L1) stably expressed in murine pre-B 300-19 cells responds selectively to I-309 with intracellular Ca2+ mobilization and chemotaxis (Kd ~1.2 nM for 125I-I-309 binding), with no response to 20 other human chemokines tested.\",\n      \"method\": \"Stable transfection in 300-19 pre-B cells, 125I-I-309 radioligand binding, calcium mobilization, chemotaxis assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — independent replication of receptor identification with radiolabeled ligand binding affinity measurement and functional assays\",\n      \"pmids\": [\"9211859\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"TARC (CCL17) and MIP-1β (CCL4) were identified as additional functional CCR8 ligands, inducing chemotaxis in CCR8-transfected Jurkat cells.\",\n      \"method\": \"Stable transfection of Jurkat cells, chemotaxis assay\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, single transfection-based chemotaxis assay; later partially superseded by more selective ligand studies\",\n      \"pmids\": [\"9521068\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"CCR8 is preferentially expressed in Th2-polarized T cells (human and mouse) but not Th1 cells. Mouse CCR8 is also expressed in thymus and NK1.1+CD4+ T cells. I-309 and its mouse homologue TCA-3 are potent chemoattractants for Th2-polarized cells acting through CCR8.\",\n      \"method\": \"RT-PCR, Northern blot, chemotaxis assay, mouse CCR8 cloning\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cloning and functional characterization of mouse CCR8 ortholog, replicated pattern of Th2-selective expression across human and mouse systems\",\n      \"pmids\": [\"9670926\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"CCR8 expression on Th2 cells is transiently up-regulated following TCR and CD28 engagement (activation-induced), and this up-regulation occurs independently of IL-4. Functional chemotactic responsiveness to I-309 is correspondingly enhanced upon activation.\",\n      \"method\": \"Flow cytometry, chemotaxis assay, cytokine neutralization (anti-IL-4)\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional receptor upregulation demonstrated by flow cytometry and chemotaxis in polarized primary T cell subsets, single lab\",\n      \"pmids\": [\"9820476\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"CCR8 functions as a coreceptor for diverse HIV-1 strains (T-cell tropic, dual-tropic, and macrophage-tropic), and the CCR8 ligand I-309 potently inhibits HIV-1 envelope-mediated cell-cell fusion and virus infection.\",\n      \"method\": \"Cell-cell fusion assay, virus infection assay, flow cytometry, Ca2+ flux assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — functional coreceptor activity demonstrated with multiple HIV-1 strains and inhibition by endogenous ligand, replicated by additional labs (PMID:9480837, PMID:10888633, PMID:20947116)\",\n      \"pmids\": [\"9417093\", \"9480837\", \"10888633\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"HHV-8-encoded vMIP-I is a selective CCR8 agonist: it binds CCR8 with high affinity (Kd <15 nM), induces Ca2+ signals in human T cells selectively through CCR8, and acts as agonist. By contrast, viral chemokines vMIP-II and vMCC-I act as potent CCR8 antagonists (binding without inducing signaling, blocking I-309 effects). A panel of 65 chemokines was used to establish CCR8 ligand selectivity.\",\n      \"method\": \"Calcium mobilization assay, competition binding assay with 65 chemokines, antagonism assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — comprehensive ligand binding fingerprint with large panel, replicated agonist/antagonist pharmacology confirmed by independent lab (PMID:10377196)\",\n      \"pmids\": [\"10419462\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"vMIP-I (KSHV-encoded) is a specific agonist for CCR8: CCR8-transfected Y3 cells showed calcium flux and vigorous chemotaxis in response to vMIP-I, with high-affinity competitive binding, and no interaction with CCR5 or 11 other receptors tested.\",\n      \"method\": \"Calcium flux assay, in vitro chemotaxis, competition binding assay in CCR8-transfected cells\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstituted receptor function in transfected cells, independent replication of vMIP-I as CCR8 agonist across two labs\",\n      \"pmids\": [\"10377196\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"MC148, encoded by the poxvirus molluscum contagiosum, is a highly selective CCR8 antagonist: it binds only CCR8 (among 16 classified human chemokine receptors), blocks I-309-induced Ca2+ signaling and chemotaxis through CCR8 without acting as agonist, and does not affect signaling of any other chemokine receptor.\",\n      \"method\": \"Competition binding with radiolabeled chemokines, calcium mobilization assay, chemotaxis assay across 16 chemokine receptors\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — comprehensive receptor selectivity panel, dual calcium and chemotaxis functional validation, confirmed as selective antagonist\",\n      \"pmids\": [\"10620615\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"CCR8 is expressed on human umbilical vein endothelial cells (HUVECs) and mediates endothelial cell chemotaxis induced by I-309 and vMIP-I; this chemotaxis is blocked by anti-CCR8 antibody and pertussis toxin, demonstrating Gi-coupled receptor-mediated signaling in endothelial cells.\",\n      \"method\": \"Chemotaxis assay, antibody blocking, pertussis toxin inhibition, RNA blot, immunohistochemistry\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pertussis toxin and antibody blocking provide mechanistic evidence for Gi-coupled CCR8 signaling in endothelial cells, single lab\",\n      \"pmids\": [\"11133740\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"CCR8 is specifically expressed on circulating CD4+CD25+ regulatory T cells (Tregs) and mediates their chemotactic response to CCL1 and CCL22; mature dendritic cells preferentially attract Tregs by secreting CCR4 ligands CCL17 and CCL22, positioning Tregs at sites of antigen presentation.\",\n      \"method\": \"Flow cytometry, chemotaxis assay, FACS-based sorting, alloproliferative response assay\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — chemotaxis and receptor co-expression on primary human Tregs, single lab with functional migration assay\",\n      \"pmids\": [\"11560999\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"CCR8 mediates human vascular smooth muscle cell (VSMC) chemotaxis induced by CCL1 and vMIP-I via a G-protein-dependent mechanism (blocked by anti-CCR8 mAb and pertussis toxin). CCL1 also induces CCR8-dependent pro-MMP-2 mRNA and protein secretion from VSMCs, and the poxvirus CCR8 antagonist MC148 inhibited CCL1-induced MMP-2 induction, confirming CCR8 dependence.\",\n      \"method\": \"Chemotaxis assay, antibody blocking, pertussis toxin inhibition, RT-PCR, Western blot for MMP-2, MC148 antagonism\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (antibody blocking, PTX, selective antagonist, mRNA/protein) in single lab\",\n      \"pmids\": [\"14576057\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"CCR8 activation by CCL1 or vMIP-I mediates rescue from dexamethasone-induced apoptosis in murine thymic lymphoma cells and primary thymocytes via ERK-dependent signaling; the selective CCR8 antagonist MC148/vMCC-I blocks this anti-apoptotic effect, formally establishing CCR8 as the receptor responsible.\",\n      \"method\": \"Apoptosis assay, ERK phosphorylation assay, MC148 antagonism, pertussis toxin inhibition\",\n      \"journal\": \"Journal of leukocyte biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mechanistic anti-apoptotic pathway defined with selective antagonist and ERK pathway inhibition, single lab\",\n      \"pmids\": [\"12525579\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"CCR8 activation by CCL1 or vMIP-I activates the RAS/MAPK pathway (ERK1/2 phosphorylation) in BW5147 thymic lymphoma cells and CCR8-transfected CHO cells, mediating anti-apoptotic activity. PD98059 (MEK inhibitor) and dominant-negative M-RAS blocked CCL1 anti-apoptotic activity.\",\n      \"method\": \"ERK phosphorylation assay, CHO transfection, MEK inhibitor (PD98059), dominant-negative M-RAS expression, apoptosis assay\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pathway dissection with pharmacological inhibitor and dominant-negative in two cell systems, single lab\",\n      \"pmids\": [\"12645948\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Post-translational sulfation of tyrosines Y14 and Y15 in the N-terminal domain of mouse CCR8 is critical for its ligand-binding activity; Y14Y15→F14F15 double mutant showed markedly reduced sulfation and was essentially inactive for CCL1 binding and calcium flux. N-linked glycosylation at N8 and O-linked glycosylation at T10/T12 had minor effects on ligand binding.\",\n      \"method\": \"Site-directed mutagenesis (Tyr→Phe, Asn→Gln, Thr→Ala substitutions), flow cytometry with CCL1-Fc fusion, calcium flux assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — systematic mutagenesis of post-translational modification sites with functional validation by ligand binding and signaling assays, single lab with multiple orthogonal readouts\",\n      \"pmids\": [\"14736884\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"LEC (CCL16) induces chemotaxis and cell adhesion by binding to and activating both CCR1 and CCR8 transfected HEK-293 cells, though at higher molar concentrations than RANTES or I-309 respectively.\",\n      \"method\": \"Chemotaxis assay, competition binding assay in CCR1- and CCR8-transfected HEK-293 cells, neutralizing antibody validation\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional binding and chemotaxis demonstrated in transfected cells with neutralizing antibody confirmation, single lab\",\n      \"pmids\": [\"10910894\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"A nonpeptide CCR8 agonist LMD-009 selectively activates CCR8 among 20 human chemokine receptors, mediating chemotaxis, inositol phosphate accumulation, and calcium release (EC50 11–87 nM). Systematic mutagenesis of 25 amino acids identified Glu286 (VII:06) as a critical anchor-point (loss of potency ~1000-fold upon Ala substitution) and Phe254 (VI:16) as a gain-of-function site for LMD-009, defining the nonpeptide ligand-binding pocket.\",\n      \"method\": \"Mutagenesis of 29 positions targeting 25 residues, calcium release assay, chemotaxis assay, IP accumulation assay, 125I-CCL1 competition binding\",\n      \"journal\": \"Molecular pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — extensive mutagenesis (25 residues) with multiple functional readouts defining the molecular binding pocket of a nonpeptide agonist, single lab\",\n      \"pmids\": [\"17652183\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"CCR8 receptor internalization is dependent on β-arrestins 1 and 2 but independent of Gαi signaling. The N-terminus of CCL1 plays a role in ligand binding to an intrahelical site; Glu-286 (TM helix 7) is crucial for receptor trafficking to the cell surface. CCL7 selectively antagonizes CCR8 responses to vMIP-I and partial agonist Ser-CCL1 but not to CCL1 itself, suggesting allotropic binding of CCR8 ligands at distinct sites.\",\n      \"method\": \"Calcium flux assay, chemotaxis assay, receptor internalization assay, β-arrestin KD, pertussis toxin treatment, mutagenesis (Glu-286, Asp-97), partial agonist (Ser-CCL1) synthesis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — β-arrestin dependence shown by knockdown, allotropic binding supported by differential antagonism, mutagenesis, single lab\",\n      \"pmids\": [\"17023422\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"CCL1 signaling through CCR8 on Tregs induces STAT3-dependent up-regulation of FOXP3, CD39, IL-10, and granzyme B, enhancing suppressive activity. Among four human CCR8 ligands, CCL1 is unique in potentiating Treg function. A self-feeding mechanism was identified whereby CCL1 produced by Tregs at autoimmune sites up-regulates CCR8 expression on these cells. CCR8-/- mice showed impaired Treg function in EAE adoptive transfer studies.\",\n      \"method\": \"Flow cytometry, STAT3 inhibitor studies, adoptive transfer in EAE model, CCR8-/- mice, CCL1-Ig administration\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (pharmacological, genetic KO, adoptive transfer) defining CCL1-CCR8-STAT3-FOXp3 signaling axis in Tregs\",\n      \"pmids\": [\"28533380\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"CCR8 is required for CCL1-mediated macrophage aggregation and peritoneal adhesion: CCR8 is up-regulated on peritoneal macrophages by inflammatory stimuli and CCL1 itself (autocrine loop). CCL1 also up-regulates plasminogen activator inhibitor-1 mRNA in macrophages and mesothelial cells. CCR8-/- mice showed significantly reduced postoperative peritoneal adhesions.\",\n      \"method\": \"In vitro cell aggregation assay, RT-PCR, CCR8-/- mice, anti-CCL1 neutralizing antibody treatment, in vivo adhesion model\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO and antibody neutralization with in vitro and in vivo functional readouts, single lab\",\n      \"pmids\": [\"17404314\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Mast cell-derived CCL1 acts through CCR8 on CD4+ T cells to orchestrate mucosal lung inflammatory responses. CCR8 deficiency results in reduced airway hyperresponsiveness, lung inflammation, and mucus hypersecretion comparable to mast cell-deficient mice; adenoviral CCL1 delivery to mast cell-deficient mouse lungs restored these parameters, establishing a mast cell-CCL1-CCR8-T cell axis.\",\n      \"method\": \"CCR8-/- mice, mast cell-deficient mice, adenoviral gene delivery, CCL1 neutralization, airway hyperresponsiveness measurement, BALF cytokine analysis\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO, gene delivery rescue, and neutralizing antibody all convergently define the mast cell-CCL1-CCR8-T cell mechanistic axis\",\n      \"pmids\": [\"17641040\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Mouse CCL8 is a selective agonist for CCR8 but not CCR2 (distinguishing it from other MCP chemokines). CCR8 expression defines a population of highly differentiated inflammatory Th2 cells enriched for IL-5. Ccr8- and Ccl8-deficient mice had markedly less eosinophilic inflammation than wild-type mice in a chronic atopic dermatitis model. Adoptive transfer experiments established CCR8 as a key regulator of Th2 cell recruitment into allergen-inflamed skin.\",\n      \"method\": \"Calcium flux, chemotaxis assay in CCR8-transfected cells, Ccr8-/- and Ccl8-/- mouse models, adoptive transfer, flow cytometry\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — receptor usage defined in transfected cells plus genetic KO models and adoptive transfer across multiple experimental approaches\",\n      \"pmids\": [\"21217759\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Human CCR8 is a receptor for CCL18: CCL18 induced chemotaxis and calcium flux in CCR8-transfected cells, bound with high affinity, induced CCR8 internalization, and competed for CCL1 binding. CCL1 and CCL18 induced heterologous cross-desensitization of CCR8-transfected cells and human Th2 cells. Wild-type but not Ccr8-/- mouse Th2 cells migrated in response to CCL18.\",\n      \"method\": \"Chemotaxis assay, calcium flux, radiolabeled competition binding, receptor internalization, cross-desensitization assay, Ccr8-/- mice\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods including genetic KO confirmation, receptor internalization, and cross-desensitization in both transfected cells and primary cells\",\n      \"pmids\": [\"23999500\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"C-terminal clipping of CCL1/I-309 by carboxypeptidase M (CPM) augments CCR8-mediated intracellular calcium release and anti-apoptotic activity while reducing direct CCL1 binding to CCR8, demonstrating that proteolytic processing modulates the CCL1-CCR8 signaling axis.\",\n      \"method\": \"In vitro enzymatic cleavage by CPM, mass spectrometry, calcium flux assay, CCR8 binding assay, apoptosis assay, carboxypeptidase inhibitor control\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro enzymatic processing with mass spectrometry verification and multiple functional assays, single lab\",\n      \"pmids\": [\"22479563\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CCR8 on CD301b+ dendritic cells (DCs) is required for their migration from the subcapsular sinus into lymph node parenchyma after allergen exposure. CCR8 ligand CCL8 is produced by CD169+SIGN-R1+ macrophages in interfollicular regions after allergen exposure and synergizes with CCL21 in a Src-kinase-dependent manner to promote DC migration. In CCR8-deficient mice, CD301b+ DCs accumulated in the subcapsular sinus and were unable to enter the LN parenchyma, resulting in defective Th2 differentiation.\",\n      \"method\": \"CCR8-/- mice, intravital microscopy/flow cytometry, Src-kinase inhibitor, in vitro migration assay, Th2 differentiation assay\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO phenotype with mechanistic pathway (CCL8→CCR8→Src-kinase→migration) defined by pharmacological inhibition and cellular analysis\",\n      \"pmids\": [\"30170811\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Activated ILC2s produce CCL1 (the CCR8 ligand) and are a major source of CCL1 in vivo; CCL1 signaling through CCR8 on ILC2s regulates their proliferation and supports their capacity to protect against helminthic infections (rather than primarily mediating ILC2 migration).\",\n      \"method\": \"In vitro CCL1 production assays, in vivo helminth infection model, CCR8-/- mice, proliferation assay\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO with in vitro and in vivo functional readouts, single lab, distinguishes proliferative from migratory function\",\n      \"pmids\": [\"31537642\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"CCR8 is required for LPS-triggered cytokine production (TNF-α, IL-6, IL-10) in peritoneal macrophages but not bone marrow-derived macrophages. CCR8-/- peritoneal macrophages showed attenuated c-Jun N-terminal kinase activity and NF-κB signaling after LPS treatment, revealing cross-talk between CCR8 and TLR-4 signaling pathways. The CCR8 antagonist R243 recapitulated CCR8-/- phenotypes.\",\n      \"method\": \"CCR8-/- mice, ELISA, CCR8 antagonist R243, JNK assay, NF-κB signaling assay, in vivo peritoneal adhesion and colitis models\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO corroborated by pharmacological antagonist, signaling pathway defined by JNK and NF-κB assays, single lab\",\n      \"pmids\": [\"24714157\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CCR8 expression on tumor-infiltrating Tregs results from TCR-mediated triggering in an NF-κB-dependent fashion. CCR8 protein is selectively prominent on highly activated, strongly suppressive tumor-infiltrating Treg subpopulations in both mouse and human tumors, with minimal CCR8-positivity on peripheral Tregs. Depletion of CCR8+ ti-Tregs by ADCC-prone anti-CCR8 nanobody-Fc in a NK-cell-dependent manner elicited antitumor immunity and reduced tumor growth; ADCC-deficient blocking antibody had no effect, indicating that Treg depletion (not CCR8 blockade) is the mechanism of antitumor activity.\",\n      \"method\": \"Single-cell RNA-seq, flow cytometry, NF-κB inhibitor, nanobody-Fc constructs with/without ADCC, NK cell depletion, syngeneic mouse tumor models (LLC-OVA, MC38)\",\n      \"journal\": \"Journal for immunotherapy of cancer\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — NF-κB dependence of CCR8 expression tested pharmacologically, ADCC mechanism confirmed by isotype comparison and NK depletion, supported by scRNA-seq\",\n      \"pmids\": [\"33589525\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Three cryo-EM structures of human CCR8 complexed with Gi trimers were solved in the ligand-free state and activated by nonpeptide agonists LMD-009 and ZK 756326. A conserved Y1.39Y3.32E7.39 motif in the orthosteric binding pocket plays a crucial role in chemokine and nonpeptide ligand recognition. Lack of conservation in Y1143.33 and Y1724.64 among CC chemokine receptors contributes to nonpeptide ligand selectivity for CCR8.\",\n      \"method\": \"Cryo-electron microscopy, structural analysis, mutagenesis (functional validation of key residues)\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — cryo-EM structures with functional mutagenesis validation, multiple structures across ligand-free and activated states, single lab\",\n      \"pmids\": [\"38306437\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CCR8-mediated signaling is biased: human CCL1 induces cell migration via Gβγ-dependent signaling, whereas other CCR8 agonists (vCCL1, ZK756326, AZ6) induce migration independently of Gβγ. All agonists were full agonists for calcium mobilization; CCR8 agonists predominantly induce Gαi-dependent cellular impedance signaling. Small molecule agonists display higher efficacy in β-arrestin 1 recruitment, occurring independently of Gαi, classifying them as biased agonists.\",\n      \"method\": \"hCCL1-AF647 binding assay, calcium mobilization, cellular impedance, chemotaxis, β-arrestin 1/2 recruitment assay, Gβγ inhibitor (gallein), Gαi inhibitor (pertussis toxin)\",\n      \"journal\": \"Biochemical pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple signaling pathway assays with pharmacological inhibitors defining biased agonism, single lab\",\n      \"pmids\": [\"33872569\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Intracellular lactate directly elevates CCR8 expression in T cells and macrophages through histone H3K18 lactylation of the CCR8 gene promoter, as demonstrated by chromatin immunoprecipitation.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP), luciferase reporter assay, RT-qPCR, Western blot, flow cytometry\",\n      \"journal\": \"Journal of experimental & clinical cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP and luciferase reporter provide direct evidence for epigenetic (lactylation) regulation of CCR8 promoter activity, single lab\",\n      \"pmids\": [\"37770937\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CCL8 from donor kidney resident macrophages promotes recipient monocyte graft infiltration via CCR8; CCR8+ T cells (CD4, CD8, γδ) infiltrate the allograft following CCL8 induction. Blocking CCL8-CCR8 or depleting donor kidney macrophages significantly inhibited early allograft immune cell infiltration and improved allograft function.\",\n      \"method\": \"Allogeneic kidney transplant mouse model, flow cytometry, CCL8-CCR8 blocking antibody, macrophage depletion\",\n      \"journal\": \"Journal of the American Society of Nephrology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo blocking and cellular depletion experiments in transplant model, single lab\",\n      \"pmids\": [\"35973731\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Disruption of the CCL1-CCR8 axis (via CCL1/Apoe double-KO mice or CCR8 blocking antibodies in LDLR-/- mice) promoted atherosclerosis, reduced plasma IL-10, increased Th1/Th2 ratio, and decreased regulatory T cell content in aorta and spleen. In vitro flow chamber assays and in vivo intravital microscopy demonstrated CCL1 mediates leukocyte recruitment to atherosclerotic vessels.\",\n      \"method\": \"Double-KO mice (Ccl1-/-/Apoe-/-), CCR8 blocking antibody in LDLR-/- mice, intravital microscopy, in vitro flow chamber, flow cytometry, ELISA\",\n      \"journal\": \"Journal of molecular and cellular cardiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic and antibody-based disruption with multiple in vivo and in vitro readouts, single lab\",\n      \"pmids\": [\"31121182\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"TNF-α in the colorectal cancer microenvironment upregulates CCR8 expression in Tregs via the TNFR2/NF-κB signaling pathway and the FOXP3 transcription factor.\",\n      \"method\": \"Flow cytometry, Western blot, NF-κB pathway inhibition, TNFR2 knockout/blockade, luciferase reporter\",\n      \"journal\": \"Journal of molecular cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — TNFR2/NF-κB pathway defined by KO and pharmacological inhibition for CCR8 upregulation, single lab\",\n      \"pmids\": [\"37935468\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"CCR8 functions as an HIV-1 coreceptor on primary human thymocytes: 125I-I-309 bound specifically to thymocyte surfaces, I-309 inhibited HIV-1 fusion with thymocytes in a dose-dependent manner, and I-309 partially inhibited productive infection by X4, R5, and X4R5 HIV-1 strains.\",\n      \"method\": \"125I-I-309 binding assay on primary thymocytes, cell-cell fusion inhibition assay, productive HIV-1 infection assay\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct radioligand binding and functional HIV inhibition on primary cells, single lab\",\n      \"pmids\": [\"10888633\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CCL18 promotes uptake of glycosylated extracellular vesicles (EVs) by glioblastoma cells via a triple interaction involving CCR8 on recipient cells, glycans on EVs, and CCL18 as a bridging molecule. EV-induced proliferation and temozolomide resistance are neutralized by the CCR8 small molecule inhibitor R243.\",\n      \"method\": \"RNAi screening, in vitro and in vivo glioblastoma models, CCR8 inhibitor R243, flow cytometry\",\n      \"journal\": \"Journal of extracellular vesicles\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RNAi screen plus pharmacological inhibition identifying CCR8 in EV uptake mechanism, single lab\",\n      \"pmids\": [\"29696074\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CCL18 from microglia/macrophages promotes glioma cell growth and invasion via CCR8 as a functional receptor, with ACP5 (acid phosphatase 5) identified as an important downstream signaling component. This was validated in a humanized ex vivo slice model using iPSC-derived human microglia and in an in vivo GBM model.\",\n      \"method\": \"Humanized brain slice model (iPSC-derived human microglia), CCR8 receptor identification, ACP5 downstream signaling, in vivo GBM mouse model\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional receptor-ligand interaction validated in humanized ex vivo and in vivo models with downstream signaling component identified, single lab\",\n      \"pmids\": [\"35417708\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CCL1 from tumor-associated macrophages promotes esophageal squamous cell carcinoma cell motility via CCR8 on cancer cells through the Akt/PRAS40/mTOR pathway; PI3K/Akt inhibitors, CCR8 knockdown, and anti-CCR8 neutralizing antibody suppressed CCL1-induced effects.\",\n      \"method\": \"Neutralizing antibody, siRNA knockdown of CCR8, PI3K/Akt inhibitors, motility assay, Western blot\",\n      \"journal\": \"The American journal of pathology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pathway defined by pharmacological inhibitors and knockdown, multiple orthogonal interventions, single lab\",\n      \"pmids\": [\"33460563\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"CCR8+ Tregs are specifically enriched in human decidua during first-trimester pregnancy and are required for maternal-fetal tolerance. Depletion of CCR8+ dTreg cells increased fetal loss susceptibility in an abortion-prone mouse model, and adoptive transfer of CCR8+ Tregs rescued fetal loss. CCL1 produced by decidual CD49a+ natural killer cells is the primary CCR8 ligand in this context.\",\n      \"method\": \"Single-cell transcriptomics, TCR sequencing, CCR8+ Treg depletion, adoptive transfer, flow cytometry, CCL1 ELISA\",\n      \"journal\": \"Science immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic depletion and adoptive transfer rescue formally establish CCR8+ Treg requirement for maternal-fetal tolerance, ligand source identified by scRNA-seq and protein measurement\",\n      \"pmids\": [\"40249828\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CCR8 is a Gi-coupled seven-transmembrane chemokine receptor that couples to pertussis toxin-sensitive G proteins and signals through the RAS/MAPK (ERK), NF-κB, and Akt/mTOR pathways; its primary endogenous ligands are CCL1, CCL8, and CCL18, while viral chemokines vMIP-I (HHV-8), vMIP-II, and MC148 (molluscum contagiosum) act as agonist or antagonist; post-translational sulfation of N-terminal tyrosines Y14/Y15 is required for ligand binding; cryo-EM structures reveal a Y1.39Y3.32E7.39 orthosteric motif and a nonpeptide binding pocket in which Glu286 is a critical anchor; CCR8 directs Th2 cell, regulatory T cell, and dendritic cell trafficking to sites of inflammation and immune regulation, mediates anti-apoptotic signaling in thymocytes, and is selectively upregulated on tumor-infiltrating Tregs via TCR/NF-κB and TNF-α/TNFR2/NF-κB signaling and by histone H3K18 lactylation, making it a target whose depletion (via ADCC-competent antibodies) selectively eliminates tumor-resident Tregs and restores anti-tumor immunity.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"CCR8 is a Gi-coupled seven-transmembrane chemokine receptor that directs the trafficking and function of Th2 cells, regulatory T cells, and dendritic cells in immune regulation and inflammation [#0, #3, #10, #24]. It was identified as the specific receptor for the CC chemokine I-309/CCL1, conferring calcium flux and chemotaxis in heterologous cells through a pertussis toxin-sensitive Gi protein [#0, #1], and additional endogenous agonists CCL8 and CCL18 were subsequently established by binding, calcium flux, and chemotaxis in transfected and Ccr8-deficient cells [#21, #22]. Viral chemokines define its pharmacology: HHV-8/KSHV vMIP-I acts as a selective agonist, whereas vMIP-II, vMCC-I, and the molluscum contagiosum-encoded MC148 are selective antagonists [#6, #7, #8]. Ligand binding requires post-translational sulfation of N-terminal tyrosines Y14/Y15 [#14], and cryo-EM of CCR8-Gi complexes resolved a conserved Y1.39Y3.32E7.39 orthosteric motif and the nonpeptide binding pocket anchored by Glu286 [#16, #28]. Downstream, CCR8 activates the RAS/ERK pathway to deliver anti-apoptotic signaling in thymocytes [#12, #13], couples to NF-\\u03baB/JNK in macrophages [#26], and engages \\u03b2-arrestin-dependent internalization and biased agonism [#17, #29]. In regulatory T cells, CCL1-CCR8-STAT3 signaling upregulates FOXP3, CD39, IL-10, and granzyme B to enhance suppression [#18], and CCR8 is selectively induced on highly suppressive tumor-infiltrating Tregs via TCR/NF-\\u03baB and TNF-\\u03b1/TNFR2/NF-\\u03baB signaling and by H3K18-lactylation of its promoter [#27, #30, #33]; ADCC-competent anti-CCR8 antibodies deplete these Tregs and restore antitumor immunity [#27]. CCR8 also serves as an HIV-1 coreceptor [#5, #34] and is required for CCR8+ Treg-mediated maternal-fetal tolerance [#38].\",\n  \"teleology\": [\n    {\n      \"year\": 1997,\n      \"claim\": \"Established CCR8's founding identity by showing the orphan receptor CY6/TER1/CKR-L1 is the specific, Gi-coupled receptor for the CC chemokine I-309/CCL1.\",\n      \"evidence\": \"Heterologous transfection of pre-B cells with calcium flux, radioligand binding, chemotaxis, and pertussis toxin inhibition\",\n      \"pmids\": [\"9207005\", \"9211859\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define downstream effector pathways beyond Gi coupling\", \"Physiological cell types expressing CCR8 only partially mapped (monocytes, thymus)\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Linked CCR8 to a defined immune compartment by demonstrating selective expression on Th2-polarized T cells and activation-induced, IL-4-independent upregulation.\",\n      \"evidence\": \"RT-PCR/Northern blot, mouse CCR8 cloning, chemotaxis, flow cytometry with anti-IL-4 neutralization in polarized primary T cells\",\n      \"pmids\": [\"9670926\", \"9820476\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not establish in vivo function of Th2-restricted CCR8\", \"Ligand repertoire beyond I-309 still ambiguous at this stage\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Identified CCR8 as an HIV-1 coreceptor whose endogenous ligand blocks viral entry, connecting the receptor to viral pathogenesis.\",\n      \"evidence\": \"Cell-cell fusion and infection assays across T-tropic, dual-tropic, and macrophage-tropic strains with I-309 inhibition; later extended to primary thymocytes\",\n      \"pmids\": [\"9417093\", \"9480837\", \"10888633\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of CCR8 versus dominant coreceptors in vivo unresolved\", \"Structural basis of gp120-CCR8 engagement not defined\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Defined CCR8's viral chemokine pharmacology, distinguishing agonist from antagonist ligands and establishing its ligand-binding fingerprint.\",\n      \"evidence\": \"Large-panel (65-chemokine) competition binding, calcium mobilization, chemotaxis, and antagonism assays in transfected cells; MC148 added selective antagonist\",\n      \"pmids\": [\"10419462\", \"10377196\", \"10620615\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve structural determinants of agonist versus antagonist behavior\", \"Physiological relevance of viral ligand engagement in infected hosts not addressed\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Established the anti-apoptotic signaling output of CCR8 by mapping CCL1/vMIP-I activation to the RAS/MEK/ERK cascade in thymocytes.\",\n      \"evidence\": \"ERK phosphorylation, MEK inhibitor (PD98059), dominant-negative M-RAS, MC148 antagonism, and apoptosis assays in thymic lymphoma and CHO cells\",\n      \"pmids\": [\"12525579\", \"12645948\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab pathway dissection\", \"In vivo relevance of thymocyte survival signaling not tested\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Identified the post-translational requirement for ligand binding by showing N-terminal tyrosine sulfation (Y14/Y15) is essential for CCL1 recognition.\",\n      \"evidence\": \"Site-directed mutagenesis (Tyr\\u2192Phe, glycosylation-site mutants) with CCL1-Fc binding and calcium flux readouts on mouse CCR8\",\n      \"pmids\": [\"14736884\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Sulfotransferase responsible not identified\", \"Generalization to human CCR8 ligands beyond CCL1 not tested in this study\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Defined the nonpeptide ligand-binding pocket and established CCR8's role in Treg suppressive programming via CCL1-STAT3-FOXP3 signaling.\",\n      \"evidence\": \"Extensive mutagenesis (25 residues) identifying Glu286 anchor; separately STAT3 inhibitor studies, CCR8-/- mice, and CCL1-Ig administration in EAE\",\n      \"pmids\": [\"17652183\", \"28533380\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism linking Glu286 to receptor trafficking versus binding only partially separated\", \"STAT3-FOXP3 axis tested largely in autoimmune, not tumor, context at this stage\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Resolved the trafficking and biased-signaling logic of CCR8 by showing \\u03b2-arrestin-dependent internalization separable from Gi signaling and allotropic ligand binding sites.\",\n      \"evidence\": \"\\u03b2-arrestin knockdown, internalization assays, Glu286/Asp97 mutagenesis, partial agonist Ser-CCL1, and differential CCL7 antagonism; later extended to biased agonism profiling\",\n      \"pmids\": [\"17023422\", \"33872569\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequences of biased agonism in vivo undefined\", \"Single-lab arrestin dependence without reciprocal genetic confirmation\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Expanded the endogenous ligand set and tissue function by establishing CCL8 (and later CCL18) as selective CCR8 agonists driving Th2 recruitment in allergic inflammation.\",\n      \"evidence\": \"Calcium flux/chemotaxis in transfected cells, Ccr8-/- and Ccl8-/- mice, adoptive transfer in atopic dermatitis and cross-desensitization with Ccr8-/- Th2 cells\",\n      \"pmids\": [\"21217759\", \"23999500\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Hierarchy among CCL1/CCL8/CCL18 in distinct tissues not fully resolved\", \"Species differences in CCL8/CCR8 usage incompletely mapped\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Defined CCR8's role in dendritic cell positioning by showing CCL8-CCR8-Src signaling is required for CD301b+ DC migration into lymph node parenchyma and downstream Th2 differentiation.\",\n      \"evidence\": \"CCR8-/- mice, intravital imaging, Src-kinase inhibition, and in vitro migration with CCL8/CCL21 synergy\",\n      \"pmids\": [\"30170811\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of CCL8/CCL21 synergy at the receptor level not defined\", \"Whether this DC axis operates outside allergen contexts unknown\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Established CCR8 as a therapeutic target on tumor-infiltrating Tregs, showing TCR/NF-\\u03baB-driven selective expression and ADCC-dependent (not blockade-dependent) Treg depletion as the antitumor mechanism.\",\n      \"evidence\": \"scRNA-seq, NF-\\u03baB inhibitor, ADCC-competent versus ADCC-deficient nanobody-Fc, NK depletion, syngeneic tumor models; epigenetic and TNFR2 routes added later\",\n      \"pmids\": [\"33589525\", \"37770937\", \"37935468\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CCR8 has an intrinsic functional role in ti-Treg suppression versus being a depletion marker not fully separated\", \"Lactylation and TNFR2 mechanisms shown in single labs\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Provided the structural framework for CCR8 ligand recognition and selectivity by resolving cryo-EM structures of CCR8-Gi complexes in ligand-free and agonist-bound states.\",\n      \"evidence\": \"Cryo-EM of CCR8-Gi with nonpeptide agonists LMD-009 and ZK 756326, plus functional mutagenesis of the Y1.39Y3.32E7.39 motif\",\n      \"pmids\": [\"38306437\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No structure with endogenous chemokine ligand bound\", \"Conformational basis of biased agonism not captured\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Extended CCR8's regulatory T cell function to reproductive immunology by establishing CCR8+ decidual Tregs as required for maternal-fetal tolerance.\",\n      \"evidence\": \"Single-cell transcriptomics, TCR sequencing, CCR8+ Treg depletion and adoptive-transfer rescue in an abortion-prone mouse model, with decidual NK-derived CCL1 identified\",\n      \"pmids\": [\"40249828\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signaling output of CCR8 in decidual Tregs not dissected\", \"Human causal evidence limited to enrichment/correlation\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unresolved whether CCR8 signaling is intrinsically required for tumor-infiltrating Treg suppressive function, or whether CCR8 is principally a depletion-enabling surface marker, and how biased/allotropic ligand engagement translates into distinct in vivo outcomes.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No genetic separation of CCR8 signaling from CCR8 expression in ti-Tregs\", \"Structural basis of biased agonism with endogenous ligands undefined\", \"Tissue-specific ligand hierarchy (CCL1/CCL8/CCL18) not resolved\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 1, 6, 7, 8]},\n      {\"term_id\": \"GO:0001618\", \"supporting_discovery_ids\": [5, 34]},\n      {\"term_id\": \"GO:0004930\", \"supporting_discovery_ids\": [0, 1]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 14, 17, 28]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 13, 29]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [3, 18, 24, 27]},\n      {\"term_id\": \"R-HSA-1500931\", \"supporting_discovery_ids\": [10, 21, 24]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [5, 27, 37]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"CCL1\", \"CCL8\", \"CCL18\", \"GNAI1\", \"ARRB1\", \"ARRB2\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}